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INTRODUCTION 
Ovary is a very important organ as it is concerned with reproduction.The 
ovary consists of mesenchymal cells which are multipotential and sex cells which 
are totipotent.So their stimulation may result in any type of tumor.
1, 2
 
Of all gynaecological cancers, ovarian malignancies representsthe greatest 
clinical challenge because of greater range and variety of tumors with uncertain 
origin, with no known premalignant lesion and variability in the rate of disease 
progression.
1
 Around 70% of patients with ovarian tumors are diagnosed only at 
advanced stages due to unavailability of effective screening method and lack of 
specific clinical presentations at early stage of the disease. 
Ovarian cancer is the eighth leading cause of cancer and fifth leading cause 
of cancer related death in females. Every year 204,000 women are diagnosed to 
have ovarian cancer and almost 125,000 women die due to ovarian cancer 
worldwide.
1
 
The histiogenesis of ovarian tumor revolves around four main components, 
mainly surface epithelium, germ cells, sex cord and specialized ovarian stroma.
2
 
Ovarian tumors can occur in all ages, but there are differences in the 
histological types during various decade of life. The predominant type of tumor 
11 
 
during younger age group arethe germ cell tumors. Sex cord stromal tumours 
occurs in women of all ages.
 
In premenopausal women 7% of tumors are frankly malignant and 30 % of 
themin postmenopausal women are malignant. 
90 to 95% of malignant tumorsof the ovary are Surface Epithelial Ovarian 
cancers and the remaining 5 to 10% constitute the Sex Cord Stromal tumors and 
the Germ cell tumors of the ovary. 
Ultrasonography is used extensively to differentiate benign and malignant 
tumors of ovary. 
This study is on the OVARIAN TUMOR MORPHOLOGICAL 
INDEXING – a quantitative analysis relating tumor morphology from 
sonographically generated images to risk malignancy. 
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AIM AND OBJECTIVES 
1. To analyse the sensitivity and specificity of a morphological 
scoring system in differentiating benign and malignant tumors of 
the ovary. 
2. To study the epidemiology of ovarian tumors. 
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REVIEW OF LITERATURE 
Ovarian cancer is the second most common of all gynaecological cancers 
and accounts for 10 – 15 % of gynaecological malignancies in developing 
countries including India.  
Ovarian cancer remains as the leading cause of all cancer related deaths 
among gynaecological malignancies in United States. The incidence of tumors of 
ovary is highest in Sweden (19.6/100,000) and the United States (15.4/100,000) 
and lowest in Japan (10.1/100,000).
3
 
Sonography is considered to be the investigation of choice for the evaluation 
of ovarian tumors due of its high sensitivity, acceptability, and low cost.Campbell 
et al in 1989 was the first to propose the use of sonography for ovarian cancer 
screening.
4
He reported a high correlation coefficient of 97% between the 
ultrasonographically detected ovarian volumes and the actual ovarian volume 
measured after oophorectomy. 
Several studies have been reported to evaluate the benefits of morphologic 
scoring systems, in quantifying and standardizing the interpretation of sonographic 
images. 
14 
 
Granberg et al in 1989 concluded that the ultrasound is highly reliable in 
predicting the characteristics of an ovarian cyst.
5
They reported that the most 
predictive characteristic feature of malignancy in an ovarian cyst is the papillary 
projections seen on the inner surface of the cyst wall. 
Sassone et al in 1991, suggested an index with four different morphologic 
features of ovarian cyst architecture, which includes wall structure, septations, cyst 
wall thickness and echogenicity.
6
 He gave a discrete score for each specific 
character and was evaluated on 143 women with ovarian tumors. The 
morphological index thus obtained was 100% sensitive and 83% specific in the 
distinguishing benign tumor from that of a malignant one. 
DePriest et al in 1994 recommended a morphologic index system, with only 
3 structural characteristics - cyst wall, ovarian volume and septae.
7
This was 
analysed on 213 women with ovarian tumors. The sensitivity was 89% and 
specificity was only 70% in predicting ovarian cancer according to his study. 
Lerner etalin 1994 used the Sassone classification system and defined the 
relative importance of the structural components by a multiple regression analysis.
8
 
Lerneretal appliedan individual score to each of the morphological components by 
simplifying the indices. The new scoring system was evaluated in 350 women with 
ovarian masses and reported a sensitivityof 97% and specificity of 77%. 
15 
 
Ferrazzi et al in 1997 designed a new scoring system that was evaluated on 
330 women with ovarian masses.
9
According to the study the sensitivity of this 
scoring system was 87% and the specificity was 67%.  
In 2001 Mol et al conducted an external validation of different 
morphological  indices including those by Lerner et al, Granberg et al, Finkler et 
al, De Priest et al, Sassone et al and Ferrazzi et al.
10
Mol et al conducted a study on 
170 ovarian tumor to compare the predictive accuracy of these scoring systems. 
They reported a lower accuracy than the original scoring indices, with a high 
sensitivity ranging from 77% to 93% and specificity ranging from 21% to 89 %.  
Ueland and collegues in 2003 evaluated the Morphology indexing and 
concluded it to be an inexpensive and accurate method in differentiating benign 
ovarian tumors and malignant ovarian tumors, it can be used as  an effective tool to 
plan the management of ovarian tumors.
11
 The useof Doppler flow studies along 
with this morphological indexing have not shown to improve the diagnostic 
accuracy of morphological indexing. 
Persistent ovarian masses and cysts studied in the Hirosaki and Kentucky 
trials showed a very low likelihood ratio for malignancy tumors - 9.4% in 
Kentucky trial and 7.0% in Hirosaki trial. By applying the morphological scoring 
indices to ultrasonographic screening system in the Hirosaki and Kentucky trials, 
16 
 
the reported a high sensitivity ranging from 80% to 90% with a positive predictive 
value of  > 20%.  
Since 1980s, the color Doppler flow sonography was considered as an 
important tool for the predictor of malignancy in ovarian tumors because Doppler 
flow gives indirect information on the metabolism and direct information on the 
vascular anatomy of the ovaries. 
Hata et al 1999, studied about the colour Doppler assessment of intratumoral 
blood flow in tumors of the ovary.
12
 
According to The National Cancer Data Base Report on Ovarian Cancer,the 
risks for ovarian cancers were associated with age, nulliparity and a family history 
of the ovarian tumors. They reported that the women‘s lifetime risk of developing 
cancer of ovaryis 1 in 70 (1.4%). Women who have a family history of one or 
more affected first-degree relatives will have an increase in risk upto 5% - 7%. It is 
been reported that only 3% -9% of the women with family history will actually 
manifest hereditary cancer syndromes. 
Approximately 90% of malignant ovarian tumors in adult are of epithelial 
tumors followed by sex cord stromal tumors (6%) and germ cell tumors (3%). 
17 
 
Shruti et al in 2008 studied on the incidence and management of ovarian 
tumours in 75 cases and reported that 90% of ovarian tumours were of epithelial 
origin, 75% were benign serous type, 20% of them were mucinous and 2% were 
endometriod type.
14
 
In 2010, GG Swamy et al did a study on 120 cases and concluded that 71.6% 
were benign, 25% were malignant and 3% were borderline tumors.
15
 About two 
third of all benign neoplasms was seen in patient between 20 to 40 years age, 
whereas two third of all malignant neoplasms were seen after the age of 40 yrs. 
The youngest patient in the study conducted by Swamy et al was 12 years of age 
and the oldest women was of 70 years of age. 
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HISTORICAL ASPECTS 
Herophilus first described the mammalian ovaries, he called it female testis. 
Soranus describes the ovary as didymus [twin]. Vesalius and De Fabrica of 
1543 labelled ovary as the testis of the uterus. Vesalius, first described the ovarian 
follicle and corpus luteum. 
In 1666, Janswammer dam explained that ―the human female testis are 
comparable to ovaria of birds‖. 
Esmond long in 1761, described all the common tumours of ovary.
 
Leonardo Da Vinci drew accurately the anatomy of the uterus and ovaries.  
Carl von Rokintansky of Vienna, his name is attached to the Rokitansky 
protuberance of dermoid tumour, also called ―dermoid mamilla‖, ―dermoid 
protuberance‖ and ―embryonic node‖. 
F.Von Werdt proposed the term ―granulosa cell tumour‖ in 1914. 
Friedrich Ernst krukenerg described a ―fibrosarcoma ovarii mucocellular 
carcinomatodes‖ in 1896 under the mistaken impression that the lesion was 
primary malignancy of ovary. In 1902 Schlagenhauter corrected the error and 
identified this lesion as metastatic carcinoma.
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Struma ovary was first described by Ludwig pick in 1903. 
Fritz brenners in 1907 published paper describing 3 cases of Brenner 
tumour, which now bear his name. 
The term ―Adenoacanthoma‖ was coined by Malcolm Dockerty of the Mayo 
clinic in 1954. 
The first histological description as germ cell tumours was given by M. 
Cherassu in 1906. 
Robert mayor first described the mixed and less differentiated forms of 
tumours which produce viriliszing effect and named as ―Adreoblastoma‖, in 1930 
it was replaced by ―Arrhenoblastoma‖. 
In 1936 Joe Vincetmeigs presented 7 cases of syndrome of ovarian fibroma, 
ascitie and hydrothorax. In 1937, Rhoads and Terrell suggested the eponym 
―Meigs syndrome‖. 
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ANATOMY OF OVARY 
The ovaries arenodular ovoid structures, located on eachside of the uterus. It 
is related to the lateral pelvic wall and attached to the posterior layer of the broad 
ligament, posteroinferior to the fallopian tubes. 
They are pink in colour with a smooth surface in young adults. With 
advancing age they become more greyish with a puckered and scarred surface due 
to repeated ovulation.They areabout 3 cm long, 1.5 cm wide. The thickness of the 
ovary is approximately 1cm. The weight of each ovary ranges from 2 - 3.5 gm.
16
 
Each ovary has 2 ends – uterine and tubal end. There are two borders – free 
border and mesoovarium. They have two surfaces – lateral and medial. 
RELATIONS: 
The upper end is also known as the tubal end. It gives attachment to the 
fimbrial end of the tubes. It is also attached to the infundibulopelvic ligament. The 
lower end is also known as the uterine end. It gives attachment to the ovarian 
ligament.
3.16
 
The free border is also called the posterior border. Upper part of free border 
is related with the uterine tube while it is related to the ureter and internal iliac 
vessels posteriorly. The mesoovarian border is also called the anterior border. It is 
21 
 
attached to the posterior leaf of the broad ligament. A cleft in this border called the 
hilum, transmits the ovarian nerves and vessels.  
The medial surface of the ovary is related to the fimbrial end of the uterine 
tube. The lateral surface is convex and lies on the peritoneal depression of the 
lateral pelvic wall, called the ovarian fossa. The lateral surface is related to the 
obturator nerves and vessels. 
BLOOD SUPPLY: 
 The ovarian artery is the main arterial supply of the ovary. Ovarian artery 
arises directly from the abdominal aorta and enters the ovary through the 
infundibulo pelvic ligament, mesoovarium and mesosalphinx. The ovaries are also 
supplied by uterine artery.
16,25
 
 The pampiniform plexus of veins coming out of the hilum form a single vein 
called the ovarian vein. The left ovarian vein drains into left renal vein and right 
ovarian vein drains into inferior venacava. 
LYMPHATIC DRAINAGE: 
 They mainly drain into pre and para aortic group of lymph nodes. 
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NERVE SUPPLY: 
 Twigs from the aortic plexus pass around the ovarian artery forms the 
ovarian plexus. Ovarian plexus consists of sympathetic fibres from T10- T11 and 
parasympathetic fibres from the vagus.
16,25
 
1. The ovarian surface epithelium ( germinal epithelium) forms the outermost 
layer 
2. The cortex is covered by the tunica albuginea, which is lined by germinal 
epithelium of waldeyer that consist of a layer of cuboidal cells. 
3. The ovarian cortex consists of stroma and ovarian follicles.
2,25
 
a.  Ovarian follicle : Contains within it the membrana granulosa, 
cumulus oophorus, the corona radiata, primary oocyte and the zona 
pellucida. The zona pellucida, antrum, theca of follicle and liquor 
folliculi are also included within the follicle.  
b. Stromal tissue: The oocytes are included within the stromal tissue, 
they are derived from the mesenchymal cells and are made up of 
connective tissue and interstitial cells. They have the ability to 
respond to hormones like leutinizing hormone or human chorionic 
gonadotropin. 
23 
 
4. The inner most layer is the medulla. The medulla and cortex cannot be 
distinctly differentiated. The medulla is made of loose connective tissue 
derived mostly from mesonephric cells. 
5. The hilum (rete ovarii):  The hilum is the point where the mesoovarium is 
attached to the ovary. It contains blood vessels and nerves, and hilus cells 
which become active in response to steroidogenesis to form tumours. 
CELLS OF THE OVARY
3,16
 (Fig – 1) 
Germ cells: At birth the oocytes represents the germ cells. Germs cellsare capable 
of reproducing tissue of all germ layers and are considered to be the cells of origin 
of teratomas. 
Granulosa cells: The granulosa cells lie in a single layer around the oocytes. They 
proliferate under the influence of FSH, forming a fluid that contains the precursor 
of the zona pellucida. 
The Call-Exner bodies,small round masses of dense pink materials 
surrounded by a rosette of granulosa cells are a specific product of granulosa cells, 
normal and neoplastic. They synthesize estrogen and various intermediates, 
including dehydroepiandrosterone. They enlarge at the time of ovulation to form 
the corpus luteum. 
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Theca cells: As the maturing graffian follicle enlarge, the immediate surrounding 
stromal cells enlarge to become rounded and plump, called luteinization. Follicle 
associated theca cells when activated produce estrogen. 
Corpus luteum: The graffian follicle ruptures in response to LH surge and expels 
the oocyte to become a corpus luteum. The corpus luteum is the main source of 
progesterone but it also synthesizes estrone and E2, and also androgen. 
The corpus luteum producesrelaxin during gestation andpuerperium, 
probably under the control of HCG.  
Hilus cells (HilarLeydig cells): These are clusters of large cells with abundant 
pink cytoplasm associated with nonmyelinated nerve fibers seen in the hilum of the 
ovary. They contain crystalloid of Reinke. Their physiological significance of in 
ovary has not been demonstrated. 
Vestigial structure: Persistence of mesonephros as isolated small duct in the 
mesovarium andaplexiform glandular structure, the rete ovarii are situated on the 
margin of the ovarian-hilar junction. 
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ETIOLOGY OF OVARIAN TUMOUR
1,2,3
 
The etiology of epithelial cancers of the ovary remains obscure. 
1. Geographic factors-more common in women of European and North 
American origin. Low incidence is seen in Japan. 
3. Menstrual factors - early menarche and late menopause 
4. Reproductive factors  
Nulliparity and low parity are at high risk. There is 40% decrease in risk 
following first pregnancy, and 14% decrease in risk following subsequent 
pregnancy. 
Elevation in circulating progestin levels during pregnancy protect from 
ovarian cancer. 
  5. Oral contraceptives
17 
Long term use of combination of contraceptive reduces the risk of ovarian 
cancer by 50%. The duration of protection last up to 25 years after the last use. 
This is due to the inhibitory effect of the OCP on ovulation. OCP protect 
against both malignant tumors of the ovaryand functional cysts of the ovarybut not 
against the benign tumors of the ovary. 
26 
 
6. Dietary factors  
There is increased risk with high fats, and low fiber, carotene and vitamin 
intake. 
7. Peritoneal irritants  
 Increased risk in women working in asbestos related industries and women 
who used talc on the perineum as they reach ovaries by ascending through the 
vagina and cervix. 
8. Family history     
 Approximately 90% of inherited cancers of the ovary are due to mutations in 
the genes BRCA1 or BRCA2.
18
 
a. BRCA 1 gene – located on chromosome 17, long arm.Germlinemutation in 
this gene are responsible for 80 – 90% of hereditary ovarian cancers. 
b. BRCA 2 gene –located on chromosome 13, long arm .Germlinemutation in 
this gene are responsible for 15% of hereditary ovarian cancers. 
The lifetime risk of ovarian cancer is approximately 39% in BRCA 1 carriers 
and 11% in BRCA 2 carriers. 
c. Hereditary Site specific ovarian cancer (HSSOC) -this is characterized by 
early onset <50 years) ovarian cancers especially if there are two or more 
27 
 
first or second degree relatives who have epithelial ovarian cancer. 
Accounting for 5 – 10 % of all hereditary ovarian tumors. 
d. Lynch syndrome II- Hereditary non polyposis colorectal cancer (HNPCC) - 
this is characterized by early onset (<50 years of age)  colon cancer (85%), 
ovarian cancer (10to12%) and endometrial cancer (40to60%)t. It is caused 
by mutation in mismatch repair MLH1 and MSH2 and makes up 5 – 10% of 
all hereditary ovarian tumors. 
9. ―Incessant ovulation theory‖19 
 In nulliparity ovarian surface epithelium form multiple cortical inclusion 
cysts (CICs) as a result of rupture of follicles due to ovulation that occurs 
cyclically. The ovarian surface epithelium, undergoes mulllerian metaplasia when 
they get embedded in the cortex, which on exposure to inflammatory stimuli and 
hormones results in DNA damage further leading to defined mutation and 
formation of endometrioid, mucinous and serous tumors of low grade. 
10. Other factors 
a. Tubal ligation has decreased risk. 
b. Increased incidence in women with bloodgroup ‗A‘. 
c. Increased risk in women who had been treated with hormone replacement 
therapy. 
28 
 
PATHOLOGY OF OVARIAN TUMORS
1,2,3,20.25
 
The ovarian tumors are categorized into 3 main types: 
1. Surface epithelial-stromal tumours 
2. Sex cord-stromal tumours 
3. Germ cell tumor 
They are classified according to the anatomic structure of origin. Further, 
each category is divided into a various  subtypes. A combinations of these various 
subtypes found adjacent or mixed together are possibly present with different 
frequencies (Fig – 2).  
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WHOHISTOLOGIC CLASSIFICATION OF OVARIAN TUMORS
2.3,20
 
I. Surface epithelial-stromal tumors 
1. Serous tumors: 
a. Benign 
i. Cystadenoma and papillary cystadenoma 
ii. Surface papilloma 
iii. Adenofibroma and cystadenofibroma 
b. Borderline malignant (carcinoma of low malignant potential) 
i. Cystadenoma and papillary cystadenoma 
ii. Surface papilloma 
iii. Adenofibroma and cystadenofibroma 
c. Malignant 
i. Adenocarcinoma, papillary adenocarcinoma 
ii. Surface papillary carcinoma 
iii. Malignant adenofibroma and cystadenofibroma 
2. Mucinous tumors, endocervical-like and intestinal-type:  
a. Benign 
i. Cystadenoma and papillary cystadenoma 
ii. Surface papilloma 
iii. Adenofibroma and cystadenofibroma 
b. Borderline 
i. Cystadenoma and papillary cystadenoma  
ii. Surface papilloma 
iii. Adenofibroma and cystadenofibroma 
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c. Malignant 
i. Adenocarcinoma and cystadenocarcinoma 
ii. Malignant adenofibroma and cystadenofibroma 
3. Endometrioid tumors:  
a. Benign 
i. Adenoma and cystadenoma 
ii. Adenofibroma and cystadenofibroma 
b. Borderline malignant 
i. Adenoma and cystadenoma 
ii. Adenofibroma and cystadenofibroma 
c. Malignant 
i. Carcinoma 
a. Adenocarcinoma 
b. Adenoacanthoma 
c. Malignant adenofibroma and cystadenofibroma 
ii. Endometroid stromal sarcomas 
iii. Mesodermal (Mullerian) mixed tumours, homologous 
andHeterologous 
4. Clear cell tumors:  
a. Benign: Adenofibrom 
b. Borderline malignant 
c. Malignant: carcinoma and adenocarcinoma 
5. Transitional cell tumors:  
a. Brenner tumor 
b. Brenner tumor of borderline malignancy 
31 
 
c. Malignant Brenner tumor 
d. Transitional cell carcinoma (non-Brenner type) 
6. Squamous cell tumors 
7. Mixed epithelial tumors (specify components): 
a. Benign 
b. Borderline 
c. Malignant 
8. Undifferentiated carcinoma 
II.  Sex cord-stromal tumors 
1. Granulosa-stromal cell tumors:  
a. Granulosa cell tumors 
b. Thecoma-fibroma group 
2. Sertoli-stromal cell tumors, androblastomas: 
a. Well differentiated 
i. Sertoli cell tumour and tubular androblastoma 
ii. Tubular androblastoma with lipid storage and Sertoli cell 
tumour  with lipid storage  
iii. Sertoli-leydig cell tumour 
iv. Leydig cell tumour and hilus cell tumour 
b. Of intermediate differentiation 
c. Poorly differentiated (sarcomatoid) 
d. With heterogenous elements 
3. Sex cord tumor with annular tubules 
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4. Gynandroblastoma 
5. Unclassified 
6. Steroid (lipid) cell tumors:  
a. Stromal luteoma 
b. Leydig cell tumor 
c. Unclassified 
III. Germ cell tumors 
a. Dysgerminoma: 
a. Variant-with syncytiotrophoblast cells 
b. Yolk sac tumors (endodermal sinus tumors): 
a. Polyvesicular vitelline tumor 
b. Hepatoid 
c. Glandular 
c. Embryonal carcinoma 
d. Polyembryoma 
e. Choriocarcinoma 
f. Teratomas:  
a. Immature 
b. Mature 
i. Solid 
ii. Cystic. Dermoid cyst 
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c. Monodermal and highly specialized 
i. Struma ovarii 
ii. Carcinoid 
iii. Struma ovarii and carcinoid 
IV. Gonadoblastoma 
a. Pure 
b. Mixed with dysgerminoma or other form of germ cell tumour 
V. Germ cell sex cord-stromal tumor of non gonadoblastoma type 
VI. Tumors of rete ovarii 
VII. Mesothelial tumors 
VIII. Tumors of uncertain origin and miscellaneous tumors 
a. Small cell carcinoma 
b. Tumour of probable Wolifian origin 
c. Hepatoid carcinoma 
IX. Gestational trophoblastic diseases 
X. Soft tissue tumors not specific to ovary 
XI. Malignant lymphomas, leukemias, and plasmacytomas 
XII. Unclassified tumors 
XIII. Secondary (metastatic) tumors 
XIV. Tumor like lesions 
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Surface Epithelial Tumors
20,21
 
 
 The surface epithelium of the ovary mimics the mesothelium, which forms 
the inner epithelialliningof the abdomen and pelvis. 
They are classified as  
1. Benign - lack of invasive behaviour and exuberant cellular proliferation. 
2. Borderline - no invasive behaviour but have exuberant cellular proliferation  
3. Malignant- invasive behaviour 
Approximately 60% of all tumors of ovary and nearly 90% of malignant 
tumors of the ovary are Surface epithelial tumors. They usually occur in middle or 
older women but very rarely can be seen in younger adults, evenbefore puberty. 
Surface epithelial stromal tumorshas 5 subtypes: 
a. Serous,  
b. Mucinous,  
c. Endometrioid,  
d. Clear Cell and  
e. Transitional Cell. 
35 
 
Malignant epithelial-stromal tumors those who lack specific differentiation are 
grouped as Undifferentiated and those without any specific subtype are classified 
as Adenocarcinomas Not Otherwise Specified (NOS). 
1. SEROUS TUMORS
20,22
 
  They are formed by the invagination of the surface ovarian epithelium and 
are lined by tall columnar ciliated epithelial cells resembling those of tubal 
epithelium. Psammoma bodies characterize serous tumors. They account for nearly 
30% of all tumors of the ovary. 
a. Benign serous tumors: 
 They account for 40% of tumors of the ovary. It is bilateral 40% of cases. 
Occurs in 4
th
 and 5
th
 decade of life (Fig -3). 
Gross: They may be cystic, papillary or adenofibromatous on macroscopic 
appearance. Size may vary from 20 – 30 cms. Typically presents with smooth 
walled cyst wall with small papillary projections.Papillary serous cystadenoma 
occurs in combination with a cyst and the papillae on the inner wall or on the outer 
surface (exophytic). Often associated with ascites and implantation of tumor 
fragments on the peritoneal surfaces giving a false impression of malignancy. 
Microscopy:Columnar epithelium with abundant cilia with microscopic papillae  
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b. Borderline serous tumors: 
They account for 10 % – 15 % of seroustype of ovarian tumors. 30% of 
tumors are bilateral, 40% of patients have small tumorlets in abdominal and pelvic 
cavity. 
Gross:They have an increased number of papillary projections. 
Microscopy: Increased complexity of the papillae of the stromal tissue with 
epithelial stratification and nuclear atypia. 
c. Malignant  serous tumors: 
They account for 75% of epithelial tumors and 25 % of serous tumors are 
malignant.60% of tumors are bilateral. Usually occurs in 6
th
 decade (Fig -4). 
Gross: They have multiple cystic loculations and solid areas. The tumor masses 
are irregular with solid or papillary areas and capsular nodularity. 
Microscopy: Even more complex growth with infiltration of the underlying stroma 
by solid tumors. Individual tumor cells have extreme degrees of atypia. 
Histologically, they may be papillary, adenopapillary or of diffuse pattern. Well 
differentiated carcinoma form glands & have papillary structures. Psammoma 
bodies are common. Poorly differentiated carcinoma has tumor cells with bizarre 
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large nuclei called giant cells, the papillae are more complex with a high degree of 
cellular budding. 
2. MUCINOUS TUMORS
20,22
: 
Mucinous tumors are made of cells which mimics those of the intestinal 
epithelium orendocervical epithelium. They account for 20 % – 25 % of all ovarian 
tumors.  
a. Benign 
They account for 20 – 25 % of all ovarian tumors. 10% of them are bilateral. 
Usually occurs in 3
rd
 and 5
th
 decade (Fig -5). 
Gross:They are smooth walled, lobulated with whitish or bluish white hue. Cut 
section shows thick, viscid mucin. The cyst is frequently multiloculated with 
papillary growth arising from septum. 
Microscopy:They are lined by a single layer of tall columnar epithelium with dark 
staining basal nucleus but without any cilia. The epithelial characteristics are like 
those of endocervix. 
b. Borderline: 
They account for 10 %- 15% of all mucinous type of ovarian tumors. These 
tumors usually occur in 4
th
 and 6
th
 decade of life. Bilaterality is seen in 40% of 
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endocervical type of borderline tumors where else only 10% of intestinal types are 
bilateral.  
They are similar to benign tumors but may have cystic chambers with 
papillary areas and few solid areas. Intestinal variety of tumors may rarely be seen 
in association with pseudo myxoma peritonei. 
c. Malignant: 
They account for 5 – 10 % of all ovarian tumors. Bilaterality is seen in 8 – 
10% of tumors. Usually occurs in 6
th
 decade of life. 
Gross: They have larger cystic spaces and solid areas with more papillary 
projections with large areas of hemorrhage and necrosis. 
Microscopy:Tumors of well differentiated type are similar to mucin secreting 
adenocarcinoma of intestinal origin. 
3. ENDOMETRIOID TUMOR:
20,21
 
They constitute 6 – 8 % of all epithelial tumors. They are formed by cells 
which are similar to those of the endometrium. They are associated with 
endometrial hyperplasia, endometriosis or endometrial carcinoma (Fig -7).   
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a. Benign: 
 Benign tumors are unusual and they account for only 2% of epithelial 
tumors. These tumors are mostly unilateral in origin. 
Gross: They are large usually measuring 10 – 25 cms. Outer surface is smooth 
with firm fibrous cut surfaces with variably sized cystic spaces. 
Microscopy:These tumors are formed of cudoidal or columnar epithelial cells 
arranged in a glandular or acinar pattern. They are adenofibromas or 
cystadenofibromas. The tumor stroma resembles that of ovary rather than that of 
endometrium. 
b. Proliferating: 
          They exhibit one of following features: multilocular cystadenofibromas or 
cystic tumours with solid friable nodules. 
Microscopy: They are low grade proliferating tumours has glands and cystic 
spaces embedded in stroma. High grade proliferating tumour shows less stroma, 
more intra cystic course, papillary and glandular proliferation. 
c. Malignant : 
 Endometrioid adenocarcinoma: Accounts for 15-20% of epithelial ovarian 
cancer and the second most common histological type. Occurs in 6
th
 decade of life. 
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13-28% of these tumors have a bilateral origin. 
Gross: These tumors have prominent solid areas with cystic spaces. The cystic 
fluid is bloody or brown. 
Microscopy: Well differentiated carcinoma have glandular growth pattern with 
irregular budding and have good prognosis. Moderately differentiated carcinoma 
show more complex glandular / micro glandular pattern.Poorly differentiated 
carcinoma have round, punched out, broader longer papilla with squamous and an 
adenomatous type of growth pattern. 
4. CLEAR CELL TUMORS:
20,21
 
Clear cell tumors are uncommon, with most of tumors having malignant 
potential. They account for 4-5% of all epithelial tumors of the ovary. They are  
usually seen in the 5
th
 decade of life. Approximately 15 – 20% of tumors are 
bilateral in origin. 
The hall mark of clear cell tumors are large polyhedral cells with eosinophilic 
granular cytoplasm or peg like ‗hob nail‘ cells with little cytoplasm and bulbous 
nuclei that bulge into lumen of cystic spaces. 
a. Benign: 
Gross: These tumor areusually cystic with mural nodules. Cystic spaces contain 
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clear fluid. Average size is 10-12 cm.  
Microscopy: Histologically, adenofibromas with tubular spaces lined by one or 
two layers of hobnail cells, clear cells, or indifferent cuboidal cells. Nuclei are 
regular in size and shape. Cells contain intracytoplasmic glycogen. 
b. Malignant : 
Gross: They are large (15-20 cm), thick walled unilocular cysts containing blood 
stained fluid. 
Microscopy: The common type is small to large sheets of polyhedral clear cells 
separated by delicate fibrovascular septa. Second type is tubulo papillary type. 
Mitosis are less frequent than in other epithelial carcinoma (2/10 HPF). 
Eosinophilic hyalinised stroma and hobnail cells are the characteristic features.  
5. TRANSITIONAL CELL TUMORS ( BRENNERS):
 20,21
 
Transitional cell tumors are made up of cells that mimicsthe bladder epithelium. 
They are formed from ovarian surface epithelium that transforms into urothelium 
like cells. 
They accounts for 2% of all primary ovarian neoplasms and are mostly unilateral. 
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a. Benign 
  Most brenner tumors are benign. Occur in 5
th
 and 6
th
 decade of life. 
Gross:Most of them are very small, well circumscribed firm, solid bosselated 
tumours with rubbery consistency and faintly lobulated grey white cut surface. 
Microscopy: They have sharply demarcated epithelial cellnests set in fibrous 
stroma (walthard nests), large cystic spaces and large blunt papillae. The epithelial 
cells are round with clear margins and eosinophilic to clear cytoplasm. The oval 
nuclei have obvious nucleoli and longitudinal grooving (Coffee bean appearance). 
Microspaces are characteristic feature of transitional cell carcinomas. 
b. Borderline : 
Gross: Cut surfaces have variable multicystic component with watery fluid into 
which friable papillary or polypoid nodules project. 
Microscopy: Coarse papillary projections and cysts are lined by multilayered 
atypical epithelium cells are similar to benign tumours. 
c. Malignant : 
Gross: They are partly cystic and contain watery or mucinous fluid and have 
shaggy lining with friable masses projecting from the wall. 
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Microscopy: These show hetrogenous solid carcinomatous proliferation. Cysts are 
lined by multilayered epithelium with hyperchromatic and pleomorphic 
nucleoli.(Fig.-8) 
6. MIXED EPITHELIAL TUMOURS:  
TheWorld Health Organization follows the 10% rule – means that the minor 
component must form at least 10% of the tumor mass to call it as a mixed tumour. 
  Common combinations include clear cell carcinoma and endometrioid 
carcinoma as both these tumours usually originate rise endometriosis.  
7. UNDIFFERENTIATED CARCINOMA:  
They accounts for 5% of all cancers of the ovary and only 1% of surface 
epithelial tumors. These tumors areformed by cells with high grade malignant 
potentials, with high nuclear atypia and loss of cytoplasmic differentiation. Two 
main types are recognized - the large cell and small cell types. About 50% are 
bilateral. 
II. SEX CORD TUMOURS OF THE OVARY 
20,23
 
Sex cord-stromal tumors make up 5% of all neoplasms of the ovary. These 
tumors arise from theca cells, granulose cells, leydig cells and the Sertoli cells. 
44 
 
Sexcord stromal tumors are usually seen in association with certain endocrine 
manifestations. 
A. GRANULOSA CELL TUMOURS 
These tumors account for 2 % of all tumors of the ovary. They originate 
from the rests of primitive granulosa cells unused in folliculogenesis. It is the 
commonest ovarian stromal tumor. Rokitansky first described these tumors. 
The hallmark of these tumours is the presence of cells that resemble those of 
follicular granulosa or their luteinized variants. 
          Around 2% of these tumor are bilateral in origin. Inhibin, secreted by 
granulosa cells to regulate FSH secretion is tumour marker. 
There are two majorforms: 
 The adult type and  
 The juvenile type 
a. Adult granulosa cell tumors: 
Constitutes 95% of GCT, usually occurs in postmenopausal women. Clinical 
presentations mainly depends on the hormone production, estrogen, they may be 
associated with endometrial hyperplasia (50%). Unopposed estrogenic stimulation 
45 
 
leads to development of endometrial carcinoma in about 5- 10 % of cases. These 
tumors are of low grade malignant potential. (Fig.-9) 
b. Juvenile granulosa cell tumors:  
These tumors constitute 5% of all ovarian GCT. These tumors are usually 
unilateral, and almost 50% of themoccur before puberty. Due to their estrogen 
production, most tumors result in precocious puberty. 
Gross: The external surface is smooth or bosselated. Cut surface appears partly 
cystic andpartly solid. Solid areas are soft or rubbery in consistency and cystic 
spaces usually contain some proteinaceous fluid or altered blood. 
Microscopy: They exhibitinsular or trabecular, macro follicular or micro follicular 
patterns. Micro follicular is common - has multiple rounded small spaces made of 
cystic degeneration of granulosa cells and they contain PAS positive material. 
These spaces are known as call-exner bodies (30-50%). 
B. THECOMA — FIBROMA GROUP OF TUMOURS 
          These tumors arise from the stromal tissue of the ovary. The thecoma,  
fibroma and fibrothecoma constitute this group of tumors. These tumors account 
for 4% of all tumors of the ovaryand they occur in both pre as well as in  post 
menopausal women (Fig -10). 
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Thecoma:  
 These tumor cells resemble the ovarian theca interna, mainly composed of 
spindle cells with lipid elements contained within the cytoplasm. Thecomas are 
usually seen in postmenopausal age group and are unilateral in origin. Thecomas 
usually have estrogenic features, suchas postmenopausal bleeding, in some cases 
may have hyperplasia of theendometrium, and even endometrial cancer. Most of 
the thecomas are characteristically benign in nature. 
Gross: Thecomas vary in size from a nodule to a large, firm rubbery solid tumour.  
Cut section appears bright yellow to orange in colour. They are almost always 
unilateral. 
Microscopy: They consist of one or two patterns.  
 Typical thecomas consists of large ill-defined nodular masses of eosinophilic 
or vacuolated cells with less fibrous connective tissue. Edema or myxoid 
change is prominent. 
 Second pattern is ‗luteinized thecoma‘ — has the appearance of fibroma or 
typical thecoma with lutein cells. 
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Fibroma: 
       Fibromas are the commonest neoplasm of the sex cord tumor group. Although 
fibroma are said to arise from nonfunctioning stromal tissue with no estrogenic 
activity, lipid-rich thecoma can have some estrogenic manifestations. 
Fibromas usually occur in the middle aged women. Fibromas are mostly 
benign and few with increase inmitotic activity are may have a malignant potential 
called the fibrosarcomas. 
On rare occasions these tumors may be bilateral and associated with basal 
cell carcinoma of nevoid type called as the Gorlinsyndrome. They may be seen in 
association with Meigs syndrome ( ascites, ovarian tumor and pleural effusion on 
right side).  
Gross: Fibromas are large tumours with slightly bosselated or smooth serosal 
surface. They vary in consistency from rubbery to stony hard solid mass. The cut –
section appears white and whorled with few regions of cystic degeneration.5% of 
cases are bilateral in origin. 
Microscopy: They consist of variably cellular bundles and intersecting 
collagenous fibrous tissue. 
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C. ANDROBLASTOMA (Sertoli — leydig cell tumours) 
(Arrhenoblastoma)
 35
 
 They account for approximately only  1 % of all sex cord — stromal 
tumours. They are characterized by presence of sertoli cells, leydig cells or 
fibroblastic cells. Only <2% in them are bilateral in origin. 
1. Sertoli cell tumours 
 Sertoli cell tumors are formed by proliferation of cells similar to rete ovarii. 
They are a rare group of sex cord-stromal ovarian tumors constituting<0.5% of all 
tumors of the ovary.They are usually seen in the 4
th
 decade of life. Sertoli cell 
tumors are non-function neoplasms, but may occasionally be able to induce sexual 
developmentprecociouslyby hormone production or rarely may cause virilization 
in girls.  
Gross: Sertoli cell tumors are usually <10cm they are solid, firm, encapsulated 
typically, yellow or brown, lobulated masses. 
Microscopy: They are formed by highly differentiated uniform tubules lined by 
single layer of cells with basal nuclei and clear cytoplasm. The epithelial cells 
contain lipid as fine droplets. 
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d. Leydig cell Tumours (Hilus cell tumour) 
Gross: These tumors are mostly unilateral and found in hilar region of ovary and 
have soft or fleshy consistency. 
Microscopy: They are formed of oval or polyhedral cells, which slender rod like 
bodies with square or tapering ends known as Reinke crystals are present. 
e. Sertoli — leydig cell tumours 
 Sertoli-Leydig cell tumors are made up of cells that mimic stromal and 
epithelial cells of the testis. They are rare sex cord-stromal ovarian tumors make 
up<0.5% of all ovarian neoplasms. They usually presents in the 3
rd
 decade of life. 
These tumors usually cause virilization in about 30% of patients, but they can also 
rarely produce estrogenic manifestations in few patients.  
 They are further classified into 5 subtypes:PoorlyDifferentiated, 
Intermediate Differentiation, Well Differentiated, Mixed and Retiform Type. 
Gross: These tumors are usually solid withcompletely or partial cystic areas. The 
tumors have a yellowish tinge appearance with vesicular or polypoid structures in 
their inner surface. Most ofthe tumors are unilateral in origin.  
Microscopy: Well differentiated tumours have tubular structures lined by cells of 
sertoli with variable numbers of mature cells of leydig between tubules. 
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          Intermediate differentiation tumours contain cells of sertoli cells, arranged 
incords, trabeculae or tubules with abundant mesenchymal stroma.  
 Poorly differentiated tumours are consists sheets of closely packed spindle 
shaped cells. 
D. GYNANDROBLASTOMA: 
 These tumours show intermingling of well differentiated ovarian and 
testicular elements. They are usually unilateral in origin. 
Gross: Gynandroblastoma are small and solid pole tumours. Cut section shows 
pink to yellow fleshy nodules. 
Microscopy: The ovarian elements resemble mature granulosa cells with call — 
exner bodies and the testicular element resemble the tubules lined by typical leydig 
and/ or sertoli cells with Reinke crystals. 
E. STEROID (LIPID) CELL TUMOUR 
Lipid cell tumors are classified as 
 Hilus cell tumor 
 Stromal luteomas 
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 Steroid cell tumors not otherwise specified  - NOS 
Gross : These appear as a soft, yellowish or yellowish - brown nodules.  
Microscopy : The cells are polyhedral or rounded, large mimicking the lutein 
cells, adrenocortical cells and the leydig cells. 
Stromal luteomas: 
 These are situated in the stroma of ovarian tissue and lack Reinke 
crystalloids. These tumors are androgenic rarely.  
Hilus cell tumours: 
 These tumors are usually andrognic and presence of Reinke crystalloids is a 
characteristic feature.  
 Both Hilus cell tumor and Stromal luteomsa occur usually in 
postmenopausal age group. These tumors are usually benign. 
Steroid cell tumours not otherwise specified: 
 They are seen in younger age group. Approximately 25 – 40% of these 
tumors are malignant. They typically produce androgen. 
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III. GERM CELL TUMOURS
20,24
 
    Germ cell tumours are the second most common of ovarian tumors only after the 
surface epithelial tumours of ovary. 
            GCT arises from totipotent germ cells which are capable of both extra 
embryonic and embryonic differentiation.  
A.DYSGERMINOMA 
 These are the most common malignant germ cell tumour of the ovary. Peak 
during 2
nd
 and 3
rd 
decades. Bilateral in 10% of cases. Serum lactate dehydrogenate 
useful in monitoring individual for disease recurrence. 
Gross: Pure dysgerminoma are solid, rapidly growing tumour and with glistening 
smooth capsule. They may be oval, round or lobulated in appearance. On cut 
section, solid and varying from firm soft rubbery and from grey pink to yellowish 
tan colour. 
Microscopy:They containaggregates or strands of uniform large cells with 
lymphocytes, plasma cells, eosinophils, and show a granulomatous reaction with 
foreign body giant cells and Langhan‘scells. 
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B. YOLK SAC TUMOURS 
 Yolk sac tumours in its pure form is the most frequent malignant germ cell 
tumour only next to dysgerminoma. The average age ranges from 16-19 years. 
Majority are unilateral.Alpha-fetoprotein is commonly produced by these tumours. 
Gross: They resemble dysgerminoma with red and yellow areas of necrosis and 
hemorrhage. 
Microscopy: Microscopic features are highly variable. Glomeruloid Schiller — 
Duval bodies are typical. The presence of diastase-resistant hyaline globules and 
PAS positive is a characteristic feature of these tumors 
C. EMBRYONAL CARCINOMA 
 Embryonal carcinoma is a raretumour. 60% of the tumours present with 
hormonal manifestations.It typically produce HCG and 75% also secrete AFP.  
Gross: They closely resembles those of yolk sac tumours. Most of the tumours are 
unilateral. 
Microscopy: They resembles testicular embryonal carcinoma. 
D.POLYEMBRYOMA 
         It is rare organoid pattern of embryonal carcinoma and consists of numerous 
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embryoid bodies, closely resembling early, embryo. Serum AFP or HCG levels or 
both may be elevated.  
 
E.CHORIOCARCINOMA 
Non gestational choriocarcinoma are extremely rare malignant tumours. 
Choriocarcinomas secrete beta HCG, which are very useful tumour marker. 
Gross: Choriocarcinoma are large, rapidly growing tumours and nearly always 
hemorrhagic. 
Microscopy: These tumour are composed of solid aggregates containing a 
centrally located cytotrophoblast and a peripherally located syncytiotrophoblast. 
F.TERATOMA 
Benign cystic teratoma:  
 Ususally occurs in the age group of 20 years to 40 years. In adults they 
account for 20% of all ovarian tumors and in children they account for 50% of all 
ovarian tumors. 
  Usually unilocular with smooth surface. They contain hair and sebaceous 
material and the wall is usually lined by skin (squamous epithelium). Other 
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structures commonly seen are teeth, cartilage, bone bronchial mucous membrane 
and thyroid tissue. Rarely intestinal mucous membrane, pancreas and liver tissue 
can be seen in the walls of dermoid cyst(Fig – 11). 
Immature teratoma (Malignant teratoma): 
 Among germ cell tumor immature teratoma are the third most common 
tumour. Usually occurs in children and young adults with a mean age of 18 yrs. 
These tumors are usually solid with a trabeculated appearance on cut section. The 
solid component of the tumor consist of bone and cartilage where else the 
sebaceous material and hair form the cystic component of the tumor (Fig -12).  
Monodermalteratoma 
Primitive neuroectodermal tumours: These primitive neuroectodermal tumours 
(PENTs) are highly malignant neoplasms. Collections of small undifferentiated 
cells (primitive neuroepithelium) exhibiting varing degree of nuclear 
pleomorphism characterise the microscopic appearance. 
Sebaceous tumours: It‘s a rare form of a monodermal teratoma. The 
characteristics necrotic ―Cheesy‖ cyst contents seen in typical teratoma are present 
but hair is absent. 
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Cystic struma ovarii: These lesions are seen in women at any age, the average age 
is 46 years. It is a smooth external surface with small foci of fibrous adhesions. A 
clear to green down fluid fills the lumen of the cysts. 
G.MIXED FORM 
 The prognosis of these tumors depend on the presence of components of 
endodermal sinus tumor, teratoma grade III or choriocarcinoma.  Tumors 
accounting for more than one third of these components have a bad prognosis. 
Tumors with less than one third of these components or when seen in association 
with teratomagarde I &II, embryonal carcinoma or dysgerminoma have a better 
prognosis. 
IV. GERM CELL -SEX CORD STROMAL TUMOURS 
Gonadoblastoma: 
 These are rare tumour that arise from a dysgenetic gonad. These tumour 
consist of both sex cord -stromal cells, that have sertoli or granulose cell and 
immature germ cells. 
V. METASTATIC TUMOURS 
 Metastatic ovarian tumors are very common, accounting for 10% of all 
malignant ovarian tumours (Fig -13). 
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 Krukenbergs tumour are secondary growths in the ovary. The common sites 
of primary are - stomach (70%), large intestine (15%) and breast (5%) 
Gross : 
 These tumours are usually bilateral with smooth surface and at times slightly 
bossed. They are freely mobile, not adherent to the adjacent structures and do not 
show any capsular infilteration. These tumors maintatin the shape of the ovary. Cut 
section shows a waxy consistency with occasional areas of cystic changes due to 
degeneration. 
Microscopy: 
 Stroma appears cellular or myxomatous. With large signetring cells which 
are ovoid with eccentric nuclei and granular cytoplasm. 
 Metastatic melanomas and renal cell carcinoma may be confused with 
granulosa cell tumor and  clear cell carcinoma. Leukemias and lymphomas may 
involve the ovaries usually in their late stage. 
VI. OVARIAN TUMOURS ASSOCIATED WITH PREGNANCY
20,26,27
 
 Benign ovarian tumors are common in pregnancy. The incidence depends on 
whether the tumor was noted on ultrasound examination – 1 in 50 live births or on 
pelvic examination – 1 in 80 live birth or those requiring laparotomy – 1 in 1000 to 
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1500 live births (Fig – 14). 
 The most common benign ovarian tumor that occurs during pregnancy is 
benign cystic teratoma (30%) followed by cystadenomas (15%). Malignant ovarian 
tumors account for only 1 to 2% of all ovarian tumors that complicate pregnancy.  
The most common malignant ovarian tumor complicating pregnancy is 
dysgerminoma (60%) followed by epithelial tumors and sex cord stromal tumors. 
 Whether benign or malignant, most of the ovarian tumors complicating 
pregnancy are unilateral in origin. 
 The optimal time for surgical intervention is 16 weeks to 18 weeks. 
Conservative surgical management for benign tumors has an excellent outcome. 
The overall 5 year survival rate for malignant ovarian tumors complicating 
pregnancy depends on the cell type, stage of the disease and on the trimester in 
which they were diagnosed. 
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CLINICAL MANIFESTATIONS 
Difference between benign and malignant ovarian tumours 
  Benign Malignant 
1. Age Reproductive age Extremes of age group (Premenarchal, 
and post-menopausal) 
2. Rapidity of 
growth 
Slow Rapid 
3. Pain and 
tenderness 
Absent unless 
complicated 
Present 
4. Surface Smooth Irregular 
5. Consistency Usually cystic Solid nodular and  irregular  
6. Number Unilateral  
15% bilateral 
75% bilateral 
7. Fixation Mobile Fixty present 
8. Ascites Usually absent (Except 
in fibroma) 
Present 
9. Oedema of 
feet 
Bilateral Unilateral with vulvaloedema 
10. Metastasis Absent Present 
11. Capsule Intact Ruptured 
12. Appearance Uniform Variegated 
13. Blood 
vessels 
No engorged vessels on 
the surface 
Large blood vessels present on the 
surface 
14. Features Unilocular cyst, few 
papillary projection, no 
solid areas 
Multilocular, highly papillated solid 
areas 
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MATERALS AND METHODS 
 This is a prospective study conducted in Department of Obstetrics and 
Gynaecology, in Govt. Rajaji Hospital, Madurai from September 2011 to August 
2012.  
The study group includes patients who were admitted at Government Rajaji 
Hospital with an ovarian tumor confirmed by transadbominal ultrasound 
examination. Totally 136 patients were evaluated during this study period. A 
standard proforma was used for collection of data.  
Transabdominal sonography was performed on all patients using a  3.5 – 
5MHztransducer. The ovary was measured in all its three dimensions, and the 
volume of the ovary was calculated with the use of the ellipsoid formula (length  x 
width x height x 0.523).  Cystic ovarian tumor with a papillary projections and 
solid areas, echogenicity, presence of septum and the presence or absence of free 
fluid in the extra tumoral space were noted. Morphology indexing was performed 
according to Ueland and collegues in 2001. 
Two different descriptive category were evaluated ( Fig15) :  
1. Volume of tumor and  
2. Morphologic features. 
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A score from 0-5 was assigned for each of the component. A total score ranging 
from  0 and 10 for every tumor. 
Observations of tumor septa, diffuse echogenicity and extra tumoral free 
fluid were includedwithin the category of morphological features. 
Following morphology indexing,eachtumor was surgically removed and 
werehistologicallyclassified according to the WHO System of classifying ovarian 
tumors. 
Statistical Tools  
The information collected regarding all the selected cases were recorded in a 
Master Chart. Data analysis was done with the help of computer using 
Epidemiological Information Package (EPI 2002).  
 Using this software, range, frequencies, percentages, means and standard 
deviations were calculated. 
Sensitivity, specificity, accuracy, positive predictive value and negative 
predictive values were calculated using the following formulae. 
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Sensitivity   =  True positivex 100 
     True positive + False negative 
 
Specificity   =  True negativex 100 
     False positive + True negative 
 
Positive predictive value =  True positive x 100 
     True positive + False positive 
 
Negative predictive value =  True negativex 100 
     True negative + False negative 
 
Accuracy   = True positive + True negative x 100 
       N 
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RESULTS 
A total of 136 ovarian tumors were studied. Table 1 illustrates the incidence 
benign, borderline and malignant tumors based on histopathological examination. 
Of the 136 ovarian tumors 92 cases were benign (67.6%), 3 were borderline (2.2%)  
and 41 were malignant (30.2%).  
Table : 1 Incidence of benign , borderline and malignant tumors as per HPE 
 
Type of tumor 
Cases 
No. % 
Benign 92 67.6 
Borderline 3 2.2 
Malignant 41 30.2 
Total 136 100 
 
The mean age was 40.5 years (range, 13–85 years).60 patients belong to the 
age group of 40 years or older and 76patients were less than 40 years of age. The 
age distribution of the patients are Illustrated in Table 2 
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Table 2 : Age distribution 
 
Age group 
(in years) 
Number of cases  
Total cases Benign Borderline Malignant 
No. % No. % No. % No. % 
11 – 20 6 6.6 - - 3 7.1 9 6.6 
21 – 30 32 35.2 - - 3 7.1 35 25.7 
31 – 40 24 26.4 - - 8 19 32 23.5 
41 – 50 14 15.4 1 33.3 8 19 23 16.9 
51 – 60 12 13 2 66.7 14 34.1 28 20.6 
Above 60  4 4.4 - - 5 11.9 9 6.6 
Total 92 100 3 100 41 100 136 100 
Range 16 – 75 45 – 52 13 – 85 13 – 85 
Mean 36.7 49.7 48.1 40.5 
S.D. 13.1 4.0 15.1 14.6 
‗p‘ 0.0001 
Significant 
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Table 3   : Parity distribution 
 
Table 3 illustrates the parity distribution of ovarian tumours. Ovarian tumors 
were common in multipara of 2 which is considered as statistically significant. 
Benign tumors were common in 2
nd
 parity women and malignant tumors were 
common in women with parity 4 and above constituting 33% and 35.7% 
respectively.  Incidence of benign tumours in nulliparous women was 22% and 
malignant tumours were 14.3%. There were 5 cases (5.4%) of ovarian tumor 
complicating pregnancy. 
 
Parity 
Number of cases  
Total cases Benign Borderline Malignant 
No. % No. % No. % No. % 
Pregnant 5 5.4 - - - - 5 5.4 
Nulli 20 22 - - 6 14.3 26 19.1 
1 8 8.6 - - 5 12.1 13 9.5 
2 28 30.7 - - 7 16.7 35 25.7 
3 12 13.2 3 100 8 19 23 16.9 
4 & above 19 20.8 - - 15 35.7 34 25 
Total 92 100 3 100 41 100 136 100 
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Table  4  : Mode of Presentation 
 
* There was more than one mode of presentation in many cases. 
Table 4 illustrates the mode of presentation of ovarian tumors. The most 
common presenting features in both benign and malignant ovarian tumours were 
pain abdomen with an incidence of 84.7% and 82.9% respectively. 
 
 
Mode of 
Presentation 
Number of cases  
Total cases Benign Borderline Malignant 
No. % No. % No. % No. % 
Mass Abdomen 23 25.3 1 33.3 13 31 37 27.2 
Pain 78 84.7 1 33.3 34 82.9 113 83.1 
Menstrual 
Disturbances 
3 3.3 2 66.7 5 11.9 10 7.4 
Post-Menopausal 
Bleeding 
1 1.1 - - - - 1 0.7 
Loss of 
Weight/Appetite 
5 5.5 - - 4 9.5 9 6.6 
Urinary Symptoms 1 1.1 - - - - 1 0.7 
White discharge 1 1.1 - - - - 1 0.7 
Vomiting 4 4.4 - - - - 4 2.9 
Asymptomatic 1 1.1 - - - - 1 0.7 
Total 92* 100 3* 100 41* 100 136* 100 
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Table  5 : Per abdomen consistency of Ovarian Tumor 
 
 
Consistency 
Number of cases  
Total cases Benign Borderline Malignant 
No. % No. % No. % No. % 
Cystic 85 93.4 3 100 8 19 96 70.6 
Firm - - - - 5 11.9 5 3.7 
Hard - - - - 17 40.5 17 12.5 
Variable - - - - 10 23.8 10 7.4 
Not palpable 7 7.7 - - 1 2.4 8 5.8 
Total 92 100 3 100 41 100 136 100 
 
Table5 illustrates the consistency of ovarian tumor on clinical examination. 
Most benign tumors were cystic in consistency (93.4%) and malignant tumors 
were hard in consistency (40.5%) and around 23.8% of malignant tumors have a 
variable consistency. 
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Table 6 : Laterality 
 
 
Laterality 
Number of cases  
Total cases Benign Borderline Malignant 
No. % No. % No. % No. % 
Unilateral 86 92.3 2 66.7 22 53.6 110 80.9 
Bilateral 6 6.6 1 33.3 19 45.2 26 19.1 
Total 92 100 3 100 41 100 136 100 
 
Table 6 illustrates the unilateral or bilateral involvement of ovaries in benign 
and malignant tumors. Most ovarian tumors were unilateral (80.9%). 92.3% of 
benign tumors were unilateral and 53.6% of malignant tumors were unilateral. 
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Table 7 illustrates the score for tumors based on the tumor volume by ultrasound. 
Score 0 1 2 3 4 5 
Tumor 
volume     
(cm3) 
< 10 10-50 50-100 100-200 200-500 >500 
 
Table  7: USG Volume Score 
 
USG Volume 
Score 
Number of cases  
Total cases Benign Borderline Malignant 
No. % No. % No. % No. % 
0 1 100 - - - - 1 0.7 
1 8 100 - - - - 8 5.9 
2 8 66.7 2 16.7 2 16.7 12 8.8 
3 23 85.2 - - 4 14.8 27 19.9 
4 27 87.1 - - 4 12.9 31 22.8 
5 25 43.9 1 1.8 31 54.4 57 41.9 
Total 92 100 3 100 41 100 136 100 
Range 
Mean 
S.D. 
1-5 
3.54 
1.23 
2-5 
3.0 
1.73 
0-5 
4.45 
1.11 
0-5 
3.84 
1.27 
‗p‘ 0.0001 (Significant) 
Most benign tumors have a score of < 4 and most of the malignant tumors are more 
have a score of>4 
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Table8: illustrates the score for tumors based on the tumor structures by 
ultrasound. 
Score 0 1 2 3 4 5 
Structure 
Smooth 
wall, 
sonolucent 
Smooth 
wall, diffuse 
echogenicity 
Wall 
thickening, 
<3mm fine 
septa 
Papillary 
projections, 
septa> 
3mm 
Complex, 
predominantly 
solid 
Complex, 
solid& cystic 
areas, 
extratumoral 
fluid 
 
Table  8 : Structural Score 
 
Structural 
Score 
Number of cases  
Total cases Benign Borderline Malignant 
No. % No. % No. % No. % 
0 56 96.6 - - 2 3.4 60 44.1 
1 19 90.5 - - 2 9.5 21 15.4 
2 6 75 - - 2 25 8 5.9 
3 5 62.5 - - 3 37.5 8 5.9 
4 2 13.3 1 6.7 12 80 15 11 
5 2 8.3 2 8.3 20 83.3 24 17.6 
Total 92 100 3 100 41 100 136 100 
Range 
Mean 
S.D. 
0-5 
0.7 
1.18 
4-5 
4.67 
0.58 
0-5 
3.88 
1.53 
0-5 
1.77 
2.0 
‗p‘ 0.0001 (Significant) 
 
Most benign tumors have a structural score <2 and most malignant tumors have a 
structural score > 3 
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Table   9: Total Morphological Score 
 
Total 
Morphological 
Score 
Number of cases  
Total cases Benign Borderline Malignant 
No. % No. % No. % No. % 
0 1 100 - - - - 1 0.7 
1 6 100 - - - - 6 4.4 
2 7 100 - - - - 7 5.1 
3 19 100 - - - - 19 14 
4 19 90.5 - - 2 9.5 21 15.4 
5 20 95.2 - - 1 4.8 21 15.4 
6 12 80 - - 3 20 15 11 
7 3 42.9 2 28.6 2 28.6 7 5.1 
8 1 12.5 - - 7 87.5 8 5.9 
9 3 20 1 6.7 11 73.3 15 11 
10 1 6.3 - - 15 93.8 16 11.8 
Total 92 100 3 100 41 100 136 100 
Range 
Mean 
S.D. 
1- 10 
4.25 
1.9 
7 – 9 
7.9 
1.2 
0 – 10 
8.5 
2.1 
0 – 10 
5.6 
2.7 
‗p‘ 0.0001 
Significant 
Table   9 illustrates the total of volume and structural score, consolidated as the 
morphological score.  
Most of the benign tumors have a score of < 5 and score of > 5 suggests 
malignancy. 
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Table 10: Results as per USG total morphological score and HPE 
 
USG total 
morphological 
score 
Number 
of cases 
Number of cases 
Benign Borderline Malignant 
No. % No. % No. % 
0 – 4 
(Benign) 
54 52 96.2 - - 2 3.73 
5 – 10 
(Malignant) 
82 40 48.8 3 3.7 39 47.6 
 
 
Table  11 : Efficacy of Morphological score with HPE as Gold standard 
Result as per 
Morphological 
score 
Number 
Of cases 
Result as per HPE 
Positive Negative 
No. % No. % 
Positive 
(Score > 5) 
82 42 51.2 40 48.8 
Negative 
(Score < 5) 
54 2 3.73 52 96.2 
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True Positive   = 42 
False Positive   = 40 
True Negative   = 51 
False negative   = 3 
Sensitivity    =  95.5 
Specificity    = 56.5 
Positive predictive value  =  51.2 
Negative predictive value =  96.3 
Accuracy    =  69.1 
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Table 12 : Morphological Score and Malignancy 
 
 
USG Morphological 
Score 
 
No. of cases 
Positive cases (Malignant + Borderline) 
As per HPE result 
No. % 
0 1 - - 
1 6 - - 
2 7 - - 
3 19 - - 
4 21 2 9.5 
Less than 
5(Negative) 
54 2 3.7 
5 21 1 4.8 
6 15 3 20 
7 7 4 57.1 
8 8 7 87.5 
9 15 12 80 
10 16 15 93.8 
5 & above (Positive) 82 42 51.2 
Total 136 44 32.3 
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Table 13: Type of Tumor 
Type of Tumor Cases 
 No. % 
1) Epithelial tumors 
 
  
a. Serous tumors 
 
74 54.5 
- Benign Serous cystadenoma 
- Benign papillary serous Cystadenofibroma 
- Borderline serous papillary cystadenoma 
- Serous cystadenocarcinoma 
- Papillary Serous cystadenocarcinoma 
 
53 
1 
2 
3 
15 
 
39 
0.7 
1.5 
2.2 
11.1 
 
b. Mucinous tumor 
 
31 22.7 
- Benign Mucinous cystadenoma 
- Borderline mucinous cystadenoma 
- Mucinous cystadenocarcinoma 
- Papillary mucinous cystadenocarcinoma 
 
21 
1 
8 
1 
15.4 
0.7 
5.9 
0.7 
c. Endometroid tumour 
- Benign 
 
 
2 
 
1.5 
 
d. Brenner tumour 
- Malignant 
 
1 0.7 
e. Undifferentiated tumor 
 
8 5.7 
- Poorly differentiated papillary carcinoma 
- Poorly differentiated carcinoma 
- Adenocarcinoma 
-  
2 
1 
5 
1.5 
0.7 
3.5 
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f. Mixed tumour 
- Benign papillaryseromucinous cystadenoma 
 
1 0.7 
2. Germ cell tumors 
 
  
         a. Teratoma 
 
11 8.1 
                   1. Immature 
                   2. Mature    (Cystic dermoid) 
1 
10 
0.7 
7.4 
3. Sex cord stromal tumor 
 
 
6 4.5 
a. Granulosa cell tumors malignant 
b. Fibrothecoma 
 
2 
4 
1.5 
3.0 
4        Metastatic Carcinoma 
Krukenbergstumor 
1 0.7 
5.    Soft tissue tumours not specific to the ovary 
(leiomyosarcoma) 
1 0.7 
Total  136 100 
 
Table 13 illustrates the incidence of various subtypes of ovarian tumors 
 
In the present study, epithelial tumors (117) were most common ovarian 
tumors followed by germ cell tumors (11).  
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DISCUSSION 
 Ovarian tumours manifest a wide spectrum of clinical, morphological and 
histological features.Clinically they may be misdiagnosed for other non-neoplastic 
conditions. 
 In this study we have analyzed 136 ovarian tumors over a period of one year 
and correlated their clinical presentation and sonographic finding with the 
histopathology. 
Benign vs. Malignant tumors: 
 Of the 136 ovarian tumors, according to histologic diagnosis 
91(66.9%)of ovariantumors were benign and 42 (30.9%) weremalignant, including 
3(2.2%) borderlinetumor masses.  
Table 15: Comparison of Incidence of Ovarian Tumors 
Study Benign Borderline Malignant 
Pilli G et al 75.2% 2.8% 20.74% 
Gupta et al 59.4% 0.58% 40% 
Couto F et al  80.7% 2.3% 16.9% 
Present study 66.9% 2.2% 30.9% 
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 The incidence of benign ovarian tumor (66.9 %) in this study is less than that 
reported by Pilli G et al and Couto et
29
 al but more than that observed by Gupta at 
al. 
Age incidence: 
Ovarian cancer may occur at any age. In our study the age incidence was 
between 13 years and 85 years. 
Table 16: comparison of Age distribution of benign tumours [%] 
Study 11 -20 21 – 30 31 – 40 41 – 50 51 – 60 >61 
Bhatiya et al (1986) 10 38.5 36.6 27.7 15.5 4.4 
RamachandranG et al (1988) 9.8 30.7 22 20.4 10.1 4.2 
Jagadheswari et al. (1991) 0 16 36 32.3 10.5 5.2 
Present study (2012) 6.6 35.2 26.4 15.4 12.1 4.4 
 
In the present study, the peak incidence of benign tumor was between the 
age group of 21-30 years (35.2 %). Similar observations were made by Bhatiya et 
al (1986) and Ramachandran G et al(1988) but this incidence is more compared to 
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that reported by Jagadheswari et al.(1991) in whose study the peak incidence of 
benign tumors was in the age group of 41 – 50 years. 
Borderline tumours were commonly seen in 45- 50 years with a mean age of 
49.7 years, as shown in table 2 
Table 17: comparisons of Age distribution of malignant tumours [%] 
Study 11 -20 21 – 30 31 – 40 41 – 50 51 – 60 >61 
Bhatiya et al (1986) 9.8 17.3 27.1 21.8 16.5 3 
Ramachandran G et al(1988) 10.5 26.3 29.5 21 9.5 3.2 
Jagadheswari et al.(1991) 13.9 16.4 19.9 27.8 17.1 2.5 
Present study (2012) 7.1 7.1 19 19 35.7 11.9 
 
In the present study, malignant tumours were commonly seen between the 
age group 51-60 years with a mean age of 48.1 years. In studies reported by 
Bhatiya et al and Ramachandran G et al the maximum incidence is seen in 31- 40 
years of age, but in Jagadheswari et al the peal incidence is seen in 41-50 years. 
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Parity: 
In the present study ovarian tumours were common in 2
nd
 parity. Of the 
benign tumours 33% were in 2
nd
 parity.Of the malignant tumours35.7% were in 4
th
 
parity and above. Similar observation was found in study done by Shahin Rashid et 
al and Shah, Vaidya et al in 1990. In the present study we have reported 5 cases of 
ovarian tumors during pregnancy and all were benign tumors. 
Clinical manifestations: 
The ovarian tumors manifest with wide variety of clinical manifestation. 
According to Sharma et al, 93.16% of the cases presented with mass abdomen and 
64.9% presented with abdominal pain. In the present study the commonest 
presenting symptom was pain abdomen (83.1%) in both benign and malignant 
tumors. 27.2% of patients presented with mass per abdomen. Similar observations 
were found in the study done by Bhattacharya MM et al
30
&Shahin Rashid et al
31
. 
Few tumors which produce hormones may cause menstrual disturbances. In 
our study, 10 cases (7.4%) presented with menstrual disturbances and 1 case 
(0.7%) with post-menopausal bleeding. According to Pilli et al in 2002, 6.7% of 
cases presented with menstrual abnormalities which were similar to our study but 
in contrary to the study conducted by Gupta et al in 1986, in which nearly 40.2% 
of cases had menstrual disorders as the presenting complaint. 
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Consistency: 
The ovarian tumors vary from cystic to solid in consistency. In the present 
study  92.3 % of benign tumors were cystic, 40.5 % of malignant tumors were hard 
and 23.8% of malignant tumors were variable in consistency.In the study 
conducted by Pilli et al in 2002, of the benign tumors 76% were cystic in the 
malignant group, 49.2% cases were hard, 44.1% were variable in consistency. 
Laterality: 
Ovarian tumors may be unilateral or bilateral; bilaterality represents the 
multicentric origin of the tumor. 6.6% of benign tumors were bilateral and 45.2% 
of malignant tumors were bilateral. According to Gupta et al 30.2 % of malignant 
tumors were bilateral. 
Histopathological types: 
Surface epithelial tumours are common tumours comprising 85.8% of all 
ovarian tumours. Among epithelial tumors, serous tumors (54.5%) were most 
common followed by mucinous tumors (22.7%). 53(39%) cases are serous 
cystadenomas. Histologically they are lined by low cuboidal to columnar 
epithelium.1 cases of cystadenofibroma was present. It was cystic and lined by low 
cuboidal epithelium. 
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Only 2 cases (1.5%) of borderline serous tumours were reported. One was 
unilateral and the other was bilateral, both were cystic in consistency. 
Histologically it has stratification of epithelial cells with mitotic activity and 
stromal penetration. 
19 malignant serous tumours were present. 10 were unilateral and 9 were 
bilateral. On gross examination 6 were cystic, 8 were solid and 4 were variable in 
consistency. Microscopically they are lined by more than one layer of columnar 
epithelium with nuclear polymorphism and hyperchromatic nuclei. 
21 mucinous cystadenoma were present, out of which 16 were multilocular 
and 5 were unilocular. The content was mucoid. The epithelial lining of the cyst 
wall is columnar with basophilic cytoplasm and basal nuclei. There was 1 case of 
borderline mucinous tumour, 8 cases of mucinous cystadenocarcinoma and 1 case 
of mucinous cystadenocarcinoma with papillary differentiation (Fig 16). 
Germ cell tumours 
These are second most common group of tumours. In germ cell tumors, 
mature benign cystic teratomas (Dermoid cyst) (7.4%) were most common. 
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The common age group was 20-30years. 2 patients were in their 5
th
 decade 
of life. Grossly they were cystic. Majority of tumours have stratified squamous 
epithelium and dermal appendages like hair, sebaceous glands etc.  
Sex cord stromal tumours: 
2 case of granulosa cell tumour presented with menstrual disturbances and 
both were malignant and solid in consistency.Histologically the cells appear 
polygonal to round with hyperchromatic nuclei with central groove and a very 
scanty cytoplasm. 
4 cases of fibrothecoma presented with mass abdomen and menstrual 
irregularities.Grossly it was variable in consistency and unilateral.Histologically it 
consists of lipid rich cells resembling theca cells. 
Mixed tumours: 
Only 1 case of benign seromucinous cystadenoma with papillary 
differentiation was reported. 
Metastatic tumor: 
 There was one case of krukenbergs tumor; the patient was operated for 
carcinoma stomach 4 years back following which she presented with mass 
abdomen. 
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Soft tissue tumours not specific to the ovary: 
1 case of leiomyosarcoma has been reported in a 40 year old P3L3 presented 
with a mass abdomen. On examination, it was a irregular mass of size 20x20 cm 
variable consistency and restricted mobility with no ascites, per operatively Left 
ovary replaced by a fleshy vascular tumour of size 20x18 cm multiloculated with 
variable consistency. On histopathology the Cells were spindle shaped cells with 
elongated nuclei and eosinophilic cytoplasam of interlacing bundles with whorled 
appearance. Pleomorphism, hyperchromatic nuclei with of mitoses 14/10 hp were 
seen( Fig 17). 
Ultrasound examination: 
With the demand for Evidence Based Medicine it has become a challenging 
task to develop a morphological index to predict the malignancy of ovarian mass 
without any surgical intervention. An ideal scoring system must be accurate, easy 
to interpret, time saving, less interobserver bias and cost effective. The use of such 
a scoring system must help in triaging the women with malignancy to an 
oncologists and avoid unwanted surgical intervention in women with benign 
tumors. 
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Several investigators have put forth many scoring system to compare the 
morphological features of the tumors.  The present Morphological Indexing is a 
modification ofthescoring system proposed by DePriest and colleagues
32
. 
Morphological scoring system: 
In the present study, one hundred and thirty six patients with ovarian tumor 
were evaluated sonographically and were operated during the study period from 
September 2011 and august 2012. The morphological characters were evaluated in 
two different descriptive characters:  
1. Volume of the tumor volume and  
2. Morphological features.(Fig.18a-g) 
 A score from 0-5 was assigned for each of the component.A total score 
ranging from  0 and 10 for every tumor. 
According to the present study the benign tumors have a mean volume score 
of 3.58 which is statistically significant (table 6). This mean deviation to the higher 
value is mainly contributed by the benign mucinous cystadenoma which were 
larger in size with a volume of > 500. The malignant ovarian tumors have a mean 
volume score of 4.45 which is statistically significant. Of the 42 malignant tumors 
31 were of volume > 5, only 2 tumors had a score 2 which were both serous 
cystadenocarcinoma. 
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In the present study, benign tumours had a mean structural score of 0.7 and 
malignant tumors had a mean structural score of 3.88 (table 7). Of the benign 
tumors most of them had a smooth wall with either sonolucent or diffuse 
echogenicity accounting for a score of 0 or 1. Of the malignant tumors most of 
them had a complex, solid and cystic areas with extramural fluid accounting for a 
score of 5. 
The total morphological score was calculated by the sum of volume and 
structural score and tabulated in table 8. The benign tumors had a mean score of 
4.25 and malignant tumors had a mean of 8.5 which was statistically significant  
with a p value  = 0.0001). The malignancy risk is directly related to the volume of 
the tumor and the various structural components each with a p value = 0.0001. 
There were only 2 cases of malignancy (3.7%) reported with a tumor 
morphological score of< 5 of the 54 ovarian tumors with a morphological score <5 
studied , compared to only 0.3% as stated in Ueland et al in 2003. In contrast there 
were 42 cases (51.2%) of malignancy with a tumor morphological Score > 5 of the 
82 tumors studied, compared to only 41% as stated by Ueland et al in 2003. 
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In the present study the morphological index score of> 5 as a predictor of 
malignancy has statistical parameters as follows:  
 Sensitivity    =  95.5 
 Specificity    = 56.5 
 Positive predictive value  =  51.2 
 Negative predictive value =  96.3 
 Accuracy    =  69.1     
 These parameters were much less than that observed by Ueland et al in 2003 
who reported a sensitivity of 98.1%, specificity of 80.7% , positive predictive 
value of 40.9%, negative predictive value  of 99.7%, and accuracy of 82.8%. 
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Table:18 Comparison of Sensitivity and  Specificity with other Studies 
Source, Year Sensitivity Specificity 
Carter et al,1988 0.62 0.95 
Granberg et al, 1991 0.82 0.92 
Sassone et al, 1991 1.0 0.83 
Lerner et al, 1994 0.97 0.77 
DePriest et al, 1994 0.89 0.70 
Yamashita et al, 1997 0.85 0.78 
Ferrazzi et al,1997 0.75 0.67 
Mol et al, 2001 0.77 – 0.93 0.21 – 0.89 
Present study  0.93 0.56 
 
 Table 18 illustrates the sensitivity and specificity of various studies. These 
individual studies to observer bias. Mol et al
10
 in 2001 did an external validation of 
these sonological indices and revealed a lower accuracy with a high sensitivity 
ranging from 77 - 93% only at the expense of a wide range in specificity ranging 
from 21 - 89%. In the present study the sensitivity is 93% and specificity is 56% 
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SUMMARY 
 
A total of 136 ovarian tumors were analysed and of these 136 ovarian 
tumors91 cases were benign (66.9%), 3 were borderline (2.2%) and 42 were 
malignant (30.9%) based on histopathology. 
The mean age was 40.5 years (range, 13–85 years).60 patients belong to the 
age group of 40 years or older and 76 patients were less than 40 years of age. 
Ovarian tumors were common in multipara of 2 which is considered as 
statistically significant. Benign tumors were common 2
nd
parity and malignant 
tumors were common in 4
th
 parity and above constituting 33% and 35.7% 
respectively.   
Incidence of benign tumours in nulliparous women was 22% and malignant 
tumours were 14.3%. There were 5 cases (5.4%) of ovarian tumor complicating 
pregnancy. 
The most common presenting features in both benign and malignant ovarian 
tumours were pain abdomen with an incidence of 84.6% and 83.3% respectively.  
Most benign tumors were cystic in consistency (93.4%) and malignant tumors 
were hard in consistency (40.5%).Around 23.8% of malignant tumors have a 
variable consistency. 
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Most ovarian tumors were unilateral (80.9%). 92.3% of benign tumors were 
unilateral and 53.6% of malignant tumors were unilateral. 
In the present study, 117 cases (85.8%) were epithelial tumors and were the 
most common ovarian tumors followed by germ cell tumors, being reported in  
only11cases (8.1%).  
The morphological scoring system as assigned by Ueland et al was used to 
calculate the morphological index. 
 A particular score is assigned to each depending on the tumor volume. Most 
benign tumors have a score of <4 and most of the malignant tumors have a score 
>4. A particular score is assigned to each depending on the tumor structure. Most 
benign tumors have a structural score of <2 and most malignant tumors have a 
structural score of > 3.The morphological index for Most of the benign tumors 
was< 5 and score of > 5 suggests malignancy. 
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The present study has the following statistical parameters:  
True Positive   = 42 
False Positive   = 40 
True Negative   = 51 
False negative   = 3 
Sensitivity    =  95.5 
Specificity    = 56.5 
Positive predictive value  =  51.2 
Negative predictive value =  96.3 
Accuracy    =  69.1 
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CONCLUSIONS 
 
The findings of the present studyconclude the following 
 Morphological scoring system is helpful in identifying women with ovarian 
tumors who are at risk for malignancy. 
 Morphological scoring system also effectively decreases the need for 
unwanted surgery in benign ovarian tumor.  
 It is easy to perform. 
 This scoring system is subjected to interobserver variation.  
 Morphologic indexing helps to standardise the ultrasound reading without 
adding costs. 
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Chart 1  
Incidence of benign , borderline and malignant tumors as 
per HPE 
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Chart  2 : Mean Age Distribution 
 
 
 
 
 
Chart  3: Parity distribution 
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Chart  3:  Parity distribution  
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Chart  4: Per abdomen c 
onsistency of Ovarian Tumor 
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Chart  5: Laterality 
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Chart  6: USG Volume Score  
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Chart  7: Structural Score 
 
 
  
 
 
 
 
 
 
 
Chart  8 :Morphological score 
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Chart  8: 
Morphological score  
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Chart  9: 
Results as per USG total  
morphological score and HPE 
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Chart  10:  
Comparison of Sensitivity and   
Specificity with other Studies 
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Fig 3.SEROUS CYST ADENOMA 
 
 
 
Stromal papillae and  columnar epithelium with abundant cilia  
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Fig 5.MUCINOUS CYSTADENOMA 
 
 
 
 
 
Tall columnar cells with           Cyst lined by columnar cells  
Apical mucin and absence of cilia    with bland basal nuclei and apical  
         mucin 
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Fig 16.BORDERLINE MUCINOUS OVARIAN TUMOR 
 
 
 
Histopathological examination shows proliferating tall columnar 
intestinal type of epithelium filled with mucin Nucleus showing 
hyperchromasia & Stratification with Few mitotic figures 
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Fig 4.PAPILLARY SEROUS CYST ADENOCARCINOMA 
 
 
 
 
 
Ki67 MALIGNANT 
 
 
 
 
 
Figure - 
 
Tumor cells arranged in solid nests and papillary pattern 
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Fig.8 BILATERAL MALIGNANT BRENNER 
 
 
Brenner tumor showing epithelial nests embedded within fibrous stroma 
 
 
Nests and islands of tumor cells infiltrating the stroma 
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Fig 6.PAPILLARY MUCINOUS CYST ADENOCARCINOMA 
 
 
Predominantly solid with few mucin containing cystic space 
 
 
Complex architecture and obvious nuclear atypia 
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Fig 11.BENIGN CYSTIC TERATOMA 
 
 
 
Areas of cartilage, hair and squamous epithelial lining 
 
Sebum, well developed teeth and hair in a mature cystic teratoma 
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Fig 13.KRUKENBERGS TUMOR 
 
 
 
Signet Ring Cells 
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Fig. 9 ADULT GRANULOSA CELL TUMOR 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Call Exner bodies 
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Fig 17.LEIOMYOSARCOMA 
 
 
Cells spindle shaped cells with elongated nuclei and eosinophilic  
cytoplasam of interlacing bundles with whorled appearance 
pleomorphism, hyperchromatic nuclei with mitoses 14/10 hp 
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Fig 12.IMMATURE TERATOMA 
 
Immature tissue differentiation towards cartilage, glands and bone. 
Grade II 
 
With Primitive neuroepithelial element 
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Fig 7.ENDOMETRIOID TUMOR 
 
Well differentiated endometrioid tumor with focal villous architecture 
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Fig 10.FIBROTHECOMA 
 
 
Pale lipid containing theca cells merge with spindle cell areas 
characteristic of fibroma 
 
 
g 
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Fig 14.OVARIAN TUMOR COMPLICATING PREGNANCY 
 
 
 
117 
 
 
Fig 18a. SMOOTH WALL, SONOLUCENT ( SCORE 0) 
 
 
 
Fig 18b.SMOOTH WALL, DIFFUSE ECHOGENICITY ( SCORE 1)  
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Fig 18c. WALL THICKENING, <3mm FINE SEPTA  ( SCORE 2) 
 
 
 
Fig 18d.PAPILLARY PROJECTIONS, SEPTA>3mm  ( SCORE 3) 
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Fig 18e. COMPLEX, PREDOMINANTLY SOLID  ( SCORE 4) 
 
Fig 18f.COMPLEX, SOLID AND CYSTIC AREAS WITH 
EXTRATUMORAL FLUID  ( SCORE 5) 
 
Fig 18g.EXTRATUMORAL FLUID  ( SCORE 5) 
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Fig 1. CELLS OF OVARY 
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Fig 2. HISTIOGENESIS OF OVARIAN TUMORS  
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Fig 15. MORPHOLOGICAL SCORING INDEX  
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KEY TO MASTER CHART  
IP NO       :      In patient Number 
G/E           :       General physical Examination 
P/S           :       Per speculum 
P  : Pain 
M  : Mass 
D  : Distension 
U/O  : Urine output 
C  : Constipation 
PM  : Post-Menopausal 
NS  :  Normal Size 
Cx, Vg H : Cervix & Vagina Healthy 
WDPV        :       White discharge per vaginum 
IR  :        Irregular Menstrual Irregularity 
Nulli  : Nulligravida 
MPV           :       Mass per vaginum  
PMB             :       Post Menopausal Bleeding 
V  : Vomiting 
Amm  :       Ammenorrhoea 
WL  :       Loss of Weight  
LA           :       Loss of Appetite 
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DM  : Diabetes Mellitus 
MA  : Menstrual Abnormalities 
F  : Fever 
PE  : Pedal Edema 
R               :       Regular 
NAD  : No Abnormalities Detected 
U  : Unilateral 
L  : Bilateral 
S  : Smooth wall 
T  : Thickened 
So  : Sonolucent 
DE  : Diffuse echogenicity 
ME  : Mixed echogenicity 
TAH   :        Total abdominal hysterectomy 
BSO  : Bilateral salpingo-oophorectomy 
RSO  :     Right salpingo-oophorectomy 
LSO             :      Left  salpingo-oophorectomy 
LOC  : Left ovarian cystectomy 
ROC  : Right ovarian cystectomy 
+  : Present 
-                   : Absent 
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PROFORMA 
Name                  :                                                   Marital status        : 
Age                    :                                                   Ip No                        : 
Date of admission   : 
Address               : 
I) Present complaints: 
 Mass per abdomen 
 Abdominal pain 
 Any menstrual irregulartities 
 Urinary symptoms 
 GIT symptoms 
 Edema of lower limbs 
 Any discharge per vaginum 
II) History of presenting illness 
Mass per abdomen 
 Onset – insidious/acute 
 Pain – present  / absent 
 Rapidity of growth – rapid / slow 
Abdominal pain 
 Present/absent 
 Onset 
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 Severity 
 associated with nausea/ vomiting 
 character of pain / squeezing / coliky / intermittent 
 aggravating / relieving factor 
Menstrual irregularities 
 Menorrhagia – yes/no 
 Amenorrhea – yes/no 
 Polymenorrhea - yes/no 
 Dysmenorrhea - yes/no 
Urinary symptoms 
 Frequency- yes/no 
 Acute retention of urine- yes/no 
 Burning micturition- yes/no 
 Difficulty in passing urine- yes/no 
GIT symptoms 
 Nausea 
 Vomiting 
 Dyspepsia 
 Constipation 
Edema of lower limbs 
 Bilateral/unilateral 
 Pitting / non pitting 
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Any discharge per vagina 
 Type / itching / foul smelling 
III) Menstrual history 
a) Age of menarche – years 
b) Past menstrual cycle 
 Regular/irregular 
 Amount of flow- scanty/ moderate/ excessive 
 Dysmenorrhea – yes/no 
 Associated clots - yes/no 
c) Attained menopause – yes/no 
IV) Obstetric history 
a) Parity 
b) Last delivery 
c) Sterilised/not 
V) Past history 
a) TB/DM/HTN/Bronchial asthma/any surgeries 
b) H/O use of oral contraceptives in the past 
VI) Family history 
a) TB/DM/HTN/Bronchial asthma/any surgeries 
b) Any similar complaints in the family 
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VII) Personal history 
a) Diet – Veg/mixed 
b) Appetite – Normal/ decreased 
c) Sleep – Normal/ disturbed 
d) Bowel – regular / irregular 
e) Bladder – Normal/ increased/ decreased 
VIII) General physical examination 
a. Built / Nourishment 
b. Clubbing/pallor/pedal edema 
c. Lympadenopathy 
d. Breast 
e. Temperature – Febrile / afebrile 
f. Pulse – 
g. BP - 
IX) Systemic examination 
a) Cardiovascular system 
b) Respiratory system 
c) Abdominal examination 
a. Inspection 
a) Shape 
b) Movement of quadrants with respiration 
c) Mass / swelling 
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 Size 
 Shape 
 Extent 
d) Any engorged vein 
e) Umblicus 
f) Hernial sites 
b. Palpation 
a) Local raise of temperature 
b) Tenderness 
c) Mass 
 Situation 
 Size 
 Extent 
 Surface 
 Consistency 
 Borders 
d) Movements with respiration 
e) Any organomegaly 
c. Percussion 
 Ascities – present / absent 
d. Auscultation 
 Any bruit- present/absent 
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X) Per speculum examination 
a) Vagina –   pale/pink/discharge/rugosity 
b) Cervix 
 position – anterior/middle/posterior 
 Erosion – Yes/no 
 Discharge – Yes/ No 
XI) Pervaginal examination 
 Cervix- consistency/ position/ mobility/tenderness 
 Uterus – size/position/ mobility/tenderness 
 Mass felt bimanually separate from uterus/ not 
 Abdominal mass movement transmitted to cervix/not 
 Forniceal examination – full/ free, tender/non tender 
XII) Per rectal examination 
 Nodulaity 
 Rectal wall 
 Pouch of douglas 
XIII) Investigations 
USG abdomen and pelvis 
 Bilateral 
 Solid/complex 
 Multiloculated 
 Thickness of cyst wall 
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 Septal thickness 
 Papillary projections. 
 Doppler study 
XIV) Treatment 
 Surgery 
 Peroperative finding 
 
 Tumour - Gross 
 Unilateral/ bilateral 
 Surface – nodular/ smooth 
 Capsule – thickened/ rupture/ hemorrhage 
 Cut section- cystic/ solid 
 Any papillary excrescens 
XV) Histopathological examination 
 
Diagnosis: 
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1 Sundari 55 13232 P PM P6L6 NAD 6x8 Cystic + + - Cx,Vg H Atropic + 2.4x4x6.8 34.14 S So - Cystic - 1 0 1 U TAH BSO
Benign Serous 
Cystadenoma
2 Bhuavaneshwari 32 13751 P R P2L2 NAD 10x8 Cystic + + - Cx,Vg H NS + 9.2x5.1x6.2 152.1 S So - Cystic - 2 0 2 U RO
Benign Serous 
Cystadenoma
3 Pandiammal 55 15626
P, M,  
D
IR P3L3 NAD 12x10 Cystic + + - Cx,Vg H NS + 9x12x5.4 305.01 S So + Cystic - 4 0 4 U TAH BSO 
Benign Serous 
Cyatadenoma 
4 Rajathi 29 15188 P,M R Nulli NAD 12x12 Cystic + - - Cx,Vg H NS + 12.7 x 10.8x11.2 803.4 S So - Cystic - 5 1 6 U RO
Benign Mucinous 
Cystadenoma
5 Gundhammal 75 16724 P,D PM P6L6 CAC 30x30 Cystic + - - Cx,Vg H Atropic + 29.5x24x21.6 7998.1 S DE - Cystic - 5 1 6 U
TAH BSO 
ICO
Benign Mucinous 
Cystadenoma
6 Mahamani 45 18044
P,u/O, 
C
PM P5L2 NAD - - - - - Cx,Vg H NS + 2.1x3.9x4 17.13 S So - Cystic - 1 0 1 U LOC
Benign Serous 
Cyatadenoma 
7 Suseela 30 17626 P R P2L2 NAD 10x10 Cystic + - - Cx,Vg H NS + 10x5x7.5 196.12 S So - Cystic - 3 0 3 U LOC
Benign Serous 
Cystadenoma
8 Deivanai 35 1809 P IR Nulli NAD 10x10 Cystic + - + Cx,Vg H Bulky + 9.8x10x6 307.5 S So - Cystic * 4 5 9 U LOC IOC
Benign Serous 
Cystadenoma
9 Alagu 45 18550 P PM P3L3 NAD 10x8 Cystic + - - Cx,Vg H NS + 10x14.5x12 910.02 S So - Cystic - 5 0 5 U TAH BSO
Benign Mucinous 
Cystadenoma
10 Fathima 28 20992 P, D IR P2L2 NAD 20x20 Firm + + - Cx,Vg H NS + 22.5x20x13.5 3177.2 T DE + Complex - 5 4 9 U TAH BSO Granulosa Cell Tumor
11 Saroja 40 20128
P,WL,L
A
R P1L1 NAD 8x8 Cystic + - - Cx,Vg H NS + 8.2x6.8x5 145.8 S DE - Cystic - 3 2 5 U
TAH BSO 
ICO
Benign Serous 
Cystadenoma
12 Chinnapillai 38 21976 P, DM R P5L5 NAD 15x10 Cystic + - - Cx,Vg H NS + 14x12x7 615.04 S So - Cystic - 5 0 5 U RO
Benign Mucinous 
Cystadenoma
13 Dharmaboopathi 60 21058 P, C PM P3L3 OBS 30x25 Hard + - - Cx,Vg H Atropic + 30.2x28.1x22.5 9986.13 T ME + Complex - 5 4 9 B
TAH BSO 
ICO
Krukenberg tumor
14 Rajathi 25 1607 P R P1L1 NAD 10x10 Cystic + - - Cx,Vg H NS + 10x8x5.2 217.56 S DE + Cystic - 3 3 6 U ROC
Benign Cystic 
Teratoma
15 Susila 40 24635 M IR P1L1 NAD 25x25 Cystic + - - Cx,Vg H Bulky + 30x21.5x18 6072.03 T DE + Complex - 5 4 9 U
TAH BSO 
ICO
Granulosa Cell Tumor
16 Indirani 51 22634
WD, 
WL
PM P4L4 NAD 15x15 Hard + - + Cx,Vg H Atropic + 13.5x14x10.2 1008.2 T ME + Complex + 5 5 10 B
TAH BSO 
ICO
Papillary Serous 
Cystadenocarcinoma
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17 Sumitha 38 24134 M R P1L1 NAD 18x15 Hard + - + Cx,Vg H NS + 14.8x20x18.5 2863.9 T DE - Complex + 5 5 10 U
TAH BSO 
ICO
Adenocarcinoma
18 Selvi 30 1487
P,WD,
V,LA
R P3L3 NAD 10x8 Cystic + - - Cx,Vg H NS + 10x 6x5 156.9 S So - Cystic - 3 0 3 U LOC
Benign Serous 
Cystadenoma
19 Alagammal 50 2508 D PM P4L3 NAD 30x30 Cystic + - - Cx,Vg H Atropic + 18x12.8x30 3614.9 T ME + Complex - 5 4 9 U
TAH BSO 
ICO
Benign Mucinous 
Cystadenoma
20 Periyakka 50 4981 P,D R P1L1 NAD 13x12 Hard + - + Cx,Vg H NS + 10.5x9.8x11 591.9 T ME + Complex + 3 5 8 B
TAH BSO 
ICO
Mucinous 
Cystadenocarcinoma
21 Mahalakshmi 20 4986 P,D R P2L0 CAC 10x10 Cystic + - - Cx,Vg H NS + 10.3x8x4.7 202.5 S DE - Cystic - 4 1 5 U
TAH BSO 
ICO
Ovarian Fibrothecoma
22 Sara 35 7125 P R P3L3 NAD 10x10 Cystic + - - Cx,Vg H NS + 10.5x7.2x5 32.9 T So - Cystic - 1 2 3 U LO
Benign Serous 
Cystadenoma
23 Mariyam Beevi 40 7107 P PM Nulli NAD - - - - - Cx,Vg H NS + 4.9x 3.1 x 5 39.7 S So - Cystic - 1 0 1 B TAH BSO
Benign Serous 
Cystadenoma
24 Sankarammal 60 5113 D PM P1L1 NAD 15x15 Hard + - + Cx,Vg H Atropic + 12.5x14x11.5 1052.5 T ME - Complex + 5 5 10 U
TAH BSO 
ICO
Mucinous 
Cystadenocarcinoma
25 Nagalakshmi 35 9268 P R Nulli NAD 15x10 Firm + - - Cx,Vg H NS + 15x12.5x13 1274.81 T ME + Complex - 5 4 9 U
Lap omental 
Biopey
Poorly Differentiated 
Carcinoma
26 Selvi 42 10354 D R P4L3 NAD 20x20 Cystic + - - Cx,Vg H NS + 15x12.5x13 1274.8 S So - Cystic - 5 0 5 U TAH BSO
Benign Serous 
Cystadenoma
27 Lourdhmary 38 12571 D R P2L2 NAD 10x15 Cystic + - - Cx,Vg H NS + 10.2x9.1x6 291.26 S So - Cystic - 4 0 4 U TAH BSO
Benign Serous 
Cystadenoma
28 SubaithaBegam 40 11904 LA R Nulli NAD 20x20 Cystic + - - Cx,Vg H NS + 18.5x12x8.2 952 S So - Cystic - 5 0 5 U TAH BSO
Benign Mucinous 
Cystadenoma
29 Bakayalakshmi 55 13085 P PM P5L5 NAD 10x8 Cystic + - - Cx,Vg H NS + 10x6x8.5 266.73 S DE - Cystic - 4 1 5 U TAH BSO
Benign Serous 
Cystadenoma
30 Petchiyammal 40 39417 P R P3L3 NAD - - - - - Cx,Vg H NS + 3.4x4.2x5.8 43.31 S So - Cystic - 2 0 2 U TAH BSO 
Benign Serous 
Cystadenoma
31 Valli 40 15765 P R P3L3 NAD 16x20
Variabl
e
- + + Cx,Vg H NS * 16.5x15x12 1553.31 T ME + Complex . 5 4 9 U
TAH BSO 
ICO
Mucinous 
Cystadenocarcinoma
32 Pandiselvi 21 8803 P R Nulli NAD 10x8 Cystic + - - Cx,Vg H NS + 8x5x6 125.52 S So - Cystic - 3 0 3 U LOC
Benign Serous 
Cyatadenoma
33 SajethaBegam 40 7226 M R P3L3 NAD 20x20 Firm + + - Cx,Vg H NS + 20x25x17.5 4576.2 S DE - Cystic - 5 1 6 U
TAH BSO 
ICO
Leiomyosarcoma
34 Panchavarnam 26 22694 P R Nulli NAD 10x8 Cystic + - - Cx,Vg H NS + 10x8 x7 292.88 S So - Cystic - 4 0 4 U LOC
Benign Serous 
Cystadenoma
35 Selvi 24 2025 P R P2L2 NAD 9x10 Cystic + - - Cx,Vg H NS + 9x7x6.5 214.16 S ME - Cystic - 4 1 5 U RO
Benign Cystic 
Teratoma
36 Shajitha 26 4038 P,V R P2L2 NAD 10x12 Cystic + - - Cx,Vg H NS + 10.2x9.5x8 405.42 S So - Cystic - 5 0 5 U RO
Benign Serous 
Cystadenoma
37 Rakkammal 58 7236 P,D R P3L3 NAD 20x20 Hard + - + Cx,Vg H NS + 18.8x15x13.2 1946.8 T ME - Complex + 5 4 9 B
TAH BSO 
ICO
Mucinous 
Cystadenocarcinoma
38 Veeralakshmi 47 9939 D,LA R P2L2 NAD 20x20 Cystic + - - Cx,Vg H NS + 16.5x15x12 1553.31 S So + Cystic + 5 5 10 U
TAH BSO 
ICO
Benign Serous 
Cystadenoma
39 Guruvammal 60 9354 P,LA,D PM P3L3 NAD 20x18
Variabl
e
+ - - Cx,Vg H Atropic + 10.5x8x11 483.25 T ME + Complex - 4 4 8 B
TAH BSO 
ICO
Poorly Differentiated 
Papillary Carcinoma
40 Veeramuthu 17 12038 MA IR Nulli NAD 8x6 Cystic + + - Cx,Vg H NS + 8x6x5 125.52 S So - Cystic - 3 0 3 U LOC
Benign Papillary  
Serous Cystadenoma
41 Malarvizhi 20 13178 P R Nulli NAD 20x18 Variable + + + Cx,Vg H NS + 21.5x16x12 2158.94 T DE + Complex + 5 5 10 U LOC ICO
Mucinous 
Cystadenocarcinoma
42 Rajeshwari 23 15308 P R Primi NAD 15x10 Hard + - - Cx,Vg H NS + 15x10x11 862.95 S So + Complex - 5 4 9 U LO
Benign Mucinous 
Cystadenoma
43 Rahmath nisha 55 15861 P PM P1L1 NAD - - - - - Cx,Vg H Atropic + 2x1.2x3 3.76 S So - Cystic - 0 0 0 U
TAH BSO 
ICO
Benign Serous 
Cystadenoma
44 Shanthi 30 14373 P R P3L3 NAD - - - - - Cx,Vg H NS + 3.2x4.8x3 21.09 S So - Cystic - 1 0 1 U LOC
Benign Serous 
Cyatadenoma
45 Ammapillai 65 15320 P PM P4L4 NAD 10x8 Cystic + - - Cx,Vg H Atropic + 10x8.2x5 214.43 S So - Cystic - 4 0 4 U TAH BSO 
Benign Serous 
Cyatadenoma
46 Sundareshwari 35 15786 P R P14 NAD 9x8 Cystic + - - Cx,Vg H NS + 9x5x6 141.21 S So - Cystic - 3 0 3 U RO
Benign Serous 
Cystadenoma
47 Subbulakshmi 30 16799
P,D,WL
,F
R P2L2 NAD 15x18 Cystic + - - Cx,Vg H NS + 18x16.5x12 1863.97 S ME - Complex - 5 3 8 U
TAH BSO 
ICO
Benign Mucinous 
Cystadenoma
48 Chellam 30 17277 P R Nulli NAD 10x7 Cystic + - - Cx,Vg H NS + 9x6x5.2 146.85 S So - Cystic - 3 0 3 U ROC
Benign Serous 
Cystadenoma
49 Sathya Bama 38 17754 P R P2L2 NAD 8x6 Cystic + - - Cx,Vg H NS + 8.6x6x4 107.94 S DE - Cystic - 3 1 4 U RSO
Benign Serous 
Cystadenoma
50 Rajam 55 18252 P R P6L6 NAD 10x8 Cystic + - - Cx,Vg H NS + 9x8x7.5 282.42 T ME - Cystic - 5 2 7 U TAH BSO
Benign Mucinous 
Cystadenoma
51 Jeyanthi 21 18756 P R Nulli NAD 14x15 Cystic + - - Cx,Vg H NS + 12x13x11.5 938.26 S DE - Cystic - 5 1 6 U LO
Benign Endometriotic 
Tumor
52 Valli 60 25253 P R P2L2 NAD 20x20 Hard + + + Cx,Vg H NS + 18x16.5x12 1863.97 T ME + Complex + 5 5 10 U
TAH BSO 
ICO
Papillary Serous 
Cystadenocarcinoma
53 Murugeshwari 22 3576 P R G2P1L1 NAD - - - - - Cx,Vg H NS + 8x5x4.5 94.14 S So - Cystic - 3 0 3 U LO
Benign Serous 
Cyatadenoma
54 Serumathy 28 2915 P,V R P1L1 NAD 10x15 Cystic + - - Cx,Vg H NS + 10x8x6.5 271.96 S ME - Cystic - 4 1 5 U LO
Benign Cystic 
Teratoma
55 Vasantha 70 11286 P R P5L5 NAD 20x22 Hard + + - Cx,Vg H NS + 25x22x18.5 5321.5 S So - Cystic - 5 0 5 B BSO
Papillary Serous 
Cystadenocarcinoma
56 Chandra 38 4629 P,D R P2L2 NAD 10x8 Cystic + - - Cx,Vg H NS + 10x8 5x5 222.27 T DE - Cystic - 4 2 6 B TAH BSO
Serous 
cystadenocarcinoma
57 Rathinam 45 4146 P R P4L4 NAD 10x10 Cystic + - - Cx,Vg H NS + 10x8x6.5 271.96 S So - Cystic - 4 0 4 U TAH BSO
Benign Serous 
Cystadenoma
58 Muthu 35 7806 P R P5L5 NAD 10x10 Cystic + - - Cx,Vg H NS + 10x8x7.2 301.24 S So - Cystic - 4 0 4 U LO
Benign Serous 
Cystadenoma
59 Vanmathi 17 8368 P R Nulli Anemic 20x25 Hard + + - Cx,Vg H NS + 21x18x14.2 2807.25 T DE + Complex - 5 4 9 U  LO ICO Immature Teratoma
60 Kamatchi 40 7799 P,D R P3L2 NAD 10x10 Cystic + - - Cx,Vg H NS + 10x6x4.5 141.21 S So - Cystic - 3 0 3 U RO
Benign Mucinous 
Cystadenoma
61 Ariyanatchi 50 11050 P,D R P4L4 NAD 15x17 Hard + + + Cx,Vg H NS + 20x18x15.5 2918.34 T So + Cystic + 5 3 8 B
TAH BSO 
ICO
Serous 
Cystadenocarcinoma
62 Meenatchi 26 12128 D R P2L2 NAD . . . . - Cx,Vg H NS + 6x4x3.5 43.93 S So - Cystic . 1 0 1 U LO
Benign Serous 
Cystadenoma
63 Parameshwari 55 5572 P,D R P1L1 NAD 10X15 Cystic + + - Cx,Vg H NS + 9.2x5x7 168.4 S So - Cystic . 3 0 3 U TAH BSO 
Benign Serous 
Cystadenoma
64 Ganesammal 35 12745 P R P2L2 NAD 10x12 Cystic + . . Cx,Vg H NS + 10x12.5x9 588.37 S So . Cystic . 5 0 5 U TAH RSO
Benign Mucinous 
Cystadenoma
65 Rani 42 13843 P,MA IR P4L2 Anemic 15x20 Variable + + + Cx,Vg H Bulky + 14.5x13x16 1577.368 T ME + Complex . 5 4 9 U
TAH BSO 
ICO
Papillary Serous 
Cystadenocarcinoma
66 Mohana 54 47472 P,D R P2L2 NAD 10x8 Cystic + - - Cx,Vg H NS + 9x7x6.5 214.16 S So - Cystic - 4 0 4 U LOC
Benign Serous 
Cystadenoma
67 Thangammal 55 16473 PMB PM P4L3 NAD 6x8 Cystic + - - Cx,Vg H Atropic + 6x5x3.5 54.91 S DE - Cystic - 2 1 3 B
TAH BSO 
ICO
Benign Papillary 
Serous 
Cystadenofibroma
68 Nagalakshmi 26 17459 Asymp R A1 NAD 9x8 Cystic + - - Cx,Vg H NS + 9x8x4.5 169.45 S ME - Cystic - 3 1 4 U LO
Benign Cystic 
Teratoma
69 Sulochana 35 2363 P R P2L2 NAD 10x8 Cystic + - - Cx,Vg H NS + 10x7x5.2 190.37 S So - Cystic - 3 0 3 U LO
Benign Serous 
Cystadenoma
70 Muthulakshmi 20 2855 P R Nulli NAD 9x8 Cystic + - - Cx,Vg H NS + 9.5x4x6.2 123.2 S So - Cystic - 3 0 3 U ROC
Benign Serous 
Cystadenoma
71 Shenbagavalli 42 2857 P R P3L3 NAD 10x8 Cystic + - - Cx,Vg H NS + 10.2x7.2x6 230.45 S So - Cystic - 4 0 4 U TAH BSO
Benign Serous 
Cystadenoma
72 Devi 47 7017 P,D R P3L3 NAD 20x25 Variable - - + Cx,Vg H NS + 20x15.2x12 1907.9 T ME + Complex + 5 5 10 U TAH BSO
Serous 
Cystadenocarcinoma
73 Mathani 24 11270 P R P2L2 NAD 10x15 Cystic + - - Cx,Vg H NS + 10.8x7.4x8 334.38 S So - Cystic - 4 0 4 U ROC
Benign Mucinous 
Cystadenoma
74 Chinnammal 60 12442 P PM P7L5 NAD - Cystic + - - Cx,Vg H Atropic + 3x4.2x3.2 21.08 T So + Cystic - 1 3 4 B TAH BSO
Papillary Serous 
Cystadenocarcinoma
75 Murugeshwari 39 12961 P R P3L3 NAD - Variable + + - Cx,Vg H NS + 5x5.6x4 58.57 T So - Cystic - 2 2 4 B
TAH BSO 
ICO
Adenocarcinoma
76 Rakku 50 14123 P PM P2L2 NAD 10x10 Variable + + - Cx,Vg H NS + 9.8x10x9 461.28 T So + Cystic - 4 3 7 B
TAH BSO 
ICO
Adenocarcinoma
77 Ezuvakka 52 1670 P R P1L1 NAD 10x10 Firm + - - Cx,Vg H NS + 9x10x8.2 385.974 S So - Cystic - 4 0 4 U TAH BSO
Papillary Serous 
Cystadenocarcinoma
78 Bakkiyam 63 13467 P PM P6L5 NAD 8x6 Hard + + + Cx,Vg H Atropic + 5x6.5x4 67.99 T ME + Complex + 2 5 7 B TAH BSO
Papillary Serous 
Cystadenocarcinoma
79 Janaki 55 51053 P PM P2L2 NAD 15x18 Cystic + - - Cx,Vg H NS + 10x15x11.5 902.17 S ME - Cystic - 5 1 6 U TAH BSO
Benign Cystic 
Teratoma
80 Tamilarasi 28 15850 P R P3L3 NAD 10x12 Cystic + - - Cx,Vg H NS + 9x7.8x5 183.57 S So - Cystic - 3 0 3 U ROC
Benign Cystic 
Teratoma
81 Kalimuthu 60 14925 P R Nulli NAD 10x15 Hard + - + Cx,Vg H NS + 12x10x10 627.6 T DE - Complex + 5 5 10 U
TAH BSO 
ICO
Papillary Serous 
Cystadenocarcinoma
82 Chittammal 35 15438 P PM P4L4 NAD 8x9 Variable + + + Cx,Vg H NS + 7x6x8 175.72 S ME + Cystic + 3 5 8 U
TAH BSO 
ICO
Papillary Serous 
Cystadenocarcinoma
83 Nagooramal 35 15876 P PH P2L2 NAD 8x8 Cystic + - - Vault H . + 7x7x5.5 140.94 S So - Cystic - 3 0 3 U LO
Benign Serous 
Cystadenoma
84 Ponnupandi 32 17843 P R P4L4 NAD 10x8 Cystic + - - Cx,Vg H NS + 10x6.5x5 169.97 T So - Cystic - 3 2 5 U
TAH BSO 
ICO
Benign Mucinous 
Cystadenoma
85 Subbuthai 43 7373 P R P2L2 NAD 10x10 Cystic + - - Cx,Vg H NS + 10x5x6.5 169.97 S DE + Cystic - 3 3 6 B
TAH BSO 
ICO
Fibrothecoma
86 Selvarani 25 20743 P PM P2L2 NAD 10x12 Cystic + - - Cx,Vg H NS + 10x5x8 209.2 S So - Cystic - 4 0 4 U LO
Benign Mucinous 
Cystadenoma
87 Andiyammal 65 23363 D PM P6L5 NAD 20x15 Cystic + - - Cx,Vg H Atropic + 20x15x18 2824.2 S DE - Complex - 4 4 9 U
TAH BSO 
ICO
Fibrothecoma
88 Nagamani 30 23343 P R Nulli NAD 10x10 Cystic + - - Cx,Vg H NS + 10x5x8 209.2 S So - Cystic - 4 0 4 U RO
Benign Serous 
Cystadenoma
89 Alagammal 70 22866 P PM Nulli NAD 8x7 Cystic + + - Cx,Vg H NS + 6.8x4x8 113.8 S So - Cystic - 3 0 3 U BSO
Benign Serous 
Cystadenoma
90 Mookammal 55 24426 P,D R P4L4 NAD 12x12 Hard + + + Cx,Vg H Atropic + 11.5x9.5x10 571.37 T ME + Complex + 5 5 10 B
TAH BSO 
ICO
Papillary Serous 
Cystadenocarcinoma
91 Nithya 19 3250 P R Mulli NAD 10x10 Cystic + - - Cx,Vg H NS + 8.5x10x7.5 333.41 S So - Cystic - 4 0 4 U LO
Benign Serous 
Cystadenoma
92 Rajathi 50 4391 P R P2L2 NAD 10x8 Cystic + - - Cx,Vg H NS + 9.5x8x6.5 258.36 S ME - Cystic - 4 1 5 B TAH BSO
Benign Cystic 
Teratoma
93 Pandeswari 25 4725 P R P2L2 NAD 7x5 Cystic + - - Cx,Vg H NS + 7x5x4.5 82.37 S So - Cystic - 2 0 2 U RO
Benign Serous 
Cyatadenoma
94 Chinnammal 26 2865 P R G2P1L1 NAD 10x6 Cystic + - - Cx,Vg H NS + 10x6x8.5 266.73 S So - Cystic - 4 0 4 U LSO
Benign Serous 
Cystadenoma
95 Pandiammal 25 11652 P R Primi NAD - - - - - Cx,Vg H NS + 10x6x4.2 131.79 S So - Cystic - 3 0 3 U LOC
Benign Serous 
Cystadenoma
96 Ramalakshmi 45 10640 P,D R P3L3 NAD 20x15 Cystic + - - Cx,Vg H NS + 20x21.5x15.2 3418.32 T ME - Complex - 5 4 9 U TAH BSO
Benign Mucinous 
Cystadenoma with 
borderline malignancy
97 Dhanalakshmi 35 12236 P,D R Nulli NAD 15x13 Cystic + - - Cx,Vg H NS + 12x11x10.5 724.87 S DE - Cystic - 5 1 6 U TAH BSO
Benign Endometriotic 
tumor 
98 Bakkiyam 50 16036 D R Mulli NAD 10x10 Cystic + - - Cx,Vg H NS + 10x8.5x9 400.09 S ME + Cystic - 4 3 7 U
TAH BSO 
ICO
Benign Serous 
Cystadenoma
99 Dhanalakshmi 60 14493 P R P2L2 NAD 15x15 Cystic + - - Cx,Vg H NS + 14x16.5x12 1449.75 S So - Cystic - 5 0 5 U TAH BSO
Benign Mucinous 
Cystadenoma
100 Pandeswari 22 13801 P,M R P6L5 NAD 15x12 Cystic + - - Cx,Vg H NS + 13.5x12x10 847.2 S So - Cystic - 5 0 5 U RO
Benign Serous 
Cystadenoma
101 Seethalakshmi 49 14778 P,D R P2L1 NAD 12x12 Cystic + - - Cx,Vg H NS + 12x11.5x9 649.56 T DE - Cystic - 5 1 6 U
TAH BSO 
ICO
Benign Papillary 
Seromucinous 
Cystadenoma
102 Lakshmi 40 18652 P,D R P2L1 NAD 10x13 Cystic + - - Cx,Vg H NS + 13x10.8x9 660.86 S So - Cystic - 5 0 5 U
TAH BSO 
ICO
Benign Mucinous 
Cystadenoma
103 Chitra 23 22712 P R P1L1 NAD 10x8 Cystic + - - Cx,Vg H NS + 10.8x7.4x8 334.38 S So - Cystic - 4 0 4 U LOC
Benign Mucinous 
Cystadenoma
104 Muthulakshmi 16 23184 P R Nulli NAD 8x6 Cystic + - - Cx,Vg H NS + 4x7x6.2 90.79 S So - Cystic - 2 0 2 U LOC
Benign Serous 
Cystadenoma
105 Eswari 25 2813D,M, MDpv R P3L2 NAD 7x8 Cystic + - - Cystocele NS + 7x3.2x4 46.86 S So - Cystic - 1 0 1 U RO
Benign Serous 
Cystadenoma
106 Meenambal 62 5906 P R P4L5 NAD 25x20 Variable + + - Cx,Vg H NS + 20x18x19.5 3671.46 T ME + Complex - 5 4 9 B Inoperable Adenocarcinoma
107 Guruvu 85 5931 P R P4L4 NAD 10x10 Cystic + - - Cx,Vg H NS + 11.2x10x9.4 550.61 T DE - Complex - 5 4 9 U TAH BSO
Poorly Differentiated 
Papillary Carcinoma
108 Sudha 39 10703 P,M R P2L2 NAD 18x16 Cystic + - - Cx,Vg H NS + 16x18x16.5 2485.3 S So - Cystic - 5 0 5 U TAH BSO 
Benign Serous 
Cystadenoma
109 Muthupandiammal 22 10866 D,M R P2L2 NAD 13x11 Cystic + - - Cx,Vg H NS + 11x6x7 462 S DE - Cystic - 4 1 5 U
TAH BSO 
ICO
Benign Serous 
Cystadenoma
110 Kamalam 52 12860 P,D R P5L3 NAD 10x10 Cystic + - - Cx,Vg H NS + 10x9x6 282.42 S So - Cystic - 4 0 4 U TAH BSO
Benign Serous 
Cystadenoma
111 Kalaiammal 41 12905 P PH P3L3 NAD 10x6 Cystic + - - Vault H . + 8x6x5 125.52 S So - Cystic - 3 0 3 U TAH BSO
Benign Serous 
Cystadenoma
112 Lakshmi 32 59852 P, V R P2L2 NAD 10x12 Cystic + - - Cx,Vg H NS + 7.6x5x4 79.49 S So - Cystic - 2 0 2 U TAH BSO
Benign Serous 
Cyatadenoma 
113 Jothi 20 18229 P,M R Primi NAD 12x7 Cystic + - - Cx,Vg H 16 wks + 10x8x6.5 271.96 S ME - Cystic - 4 1 5 U RO
Benign Cystic 
Teratoma
114 Vairakkal 56 17892 P,MA IR P4L4A1 NAD 25x15 Cystic + - - Cx,Vg H NS + 20x18.5x21.2 4102.41 S DE - Cystic - 5 1 6 U
TAH BSO 
ICO
Mucinous Papillary 
Cystadenocarcinoma
115 Ambigavathy 30 61872 D, C, PE IR P2L2 NAD 20x15 Cystic + + + Cx,Vg H NS + 15.5x12x10 972.78 T ME + Complex + 5 5 10 U
TAH BSO 
ICO
Papillary Serous 
Cystadenocarcinoma
116 Murugayee 60 19139 P, M, LA R P4L4 NAD 20x18 Cystic + + - Cx,Vg H NS + 15x16.5x18 2329.98 T ME + Complex + 5 5 10 U
TAH BSO 
ICO
Papillary Serous 
Cystadenocarcinoma
117 Laxiammal 60 19116 D R P3L2 NAD 30x20 Cystic + + - Cx,Vg H NS + 20x18x16 3012.48 T So - Complex + 5 5 10 U
TAH BSO 
ICO
Papillary Serous 
Cystadenocarcinoma
118 Mariammal 52 6309 MA IR P3L3 NAD 6x8 Cystic + - - Cx,Vg H Bulky + 6x6x5 94.14 T DE - Cystic + 2 5 7 B
TAH BSO 
ICO
Papillary serous tumor 
of borderline 
malignancy
119 panju 42 8617 P R P5L5 NAD 10x10 Hard + - - Cx,Vg H NS + 10x11x9 517.77 T DE + Complex + 5 5 10 B
TAH BSO 
ICO
Mucinous 
cystadenocarcinoma
120 Dhanalakshmi 32 927 P,D R P2L2 NAD 20x15 Cystic + - - Cx,Vg H NS + 19.6x21x18 3874.8 S So - Cystic - 5 0 5 U RO
Benign Mucinous 
Cystadenoma
121 Lakshmi 35 2076 P R P5L1 NAD 10x10 Cystic + - - Cx,Vg H NS + 12x10x11 690.36 S So + Cystic - 5 2 7 U TAH BSO
Benign Cystic 
Teratoma
122 Meera 27 5782 P R P2L2 NAD 6x7 Cystic + - - Cx,Vg H NS + 5.2x5x4 54.39 S So - Cystic - 2 0 2 U RO LSO
Benign Serous 
Cystadenoma
123 Priya 23 9028 P R Nulli NAD 9x9 Cystic + - - Cx,Vg H NS + 9x8.2x7 270.18 S So + Cystic - 4 2 6 U RO
Benign Cystic 
Teratoma
124 Bakkiyam 30 9542 P R P1L1 NAD 7x7 Cystic + - - Cx,Vg H NS + 7.2x5x6 112.96 S So - Cystic - 3 0 3 U LO
Benign Serous 
Cystadenoma
125 Guruvammal 45 9033 P,D R P2L2 NAD 20x25 Cystic + - - Cx,Vg H NS + 21x18x19.5 3855.03 S ME - Cystic - 5 1 6 U
TAH BSO 
ICO
Benign Mucinous 
Cystadenoma
126 Paapa 47 12433 P R P4L4 NAD 6x8 Cystic + - - Cx,Vg H NS + 4x6x8 100.42 S So - Cystic - 2 0 2 U LOC
Benign Serous 
Cystadenoma
127 Sundareshwari 35 15786 P R P1L1 NAD 9x10 Cystic + - - Cx,Vg H NS + 9x8x6 225.93 S So - Cystic - 4 0 4 U RO
Benign Serous 
Cystadenoma
128 Selvi 28 9013 P R P3L3 NAD 20x20 Cystic + - - Cx,Vg H NS + 20x21.5x16 3598.24 S DE - Cystic - 5 1 6 B
TAH BSO 
ICO
Ovarian Fibrothecoma
129 Chitra 25 9109 P R P2L2 NAD 20x15 Cystic + - - Cx,Vg H NS + 20x22.5x18 4257.22 S ME - Cystic - 5 1 6 U LSO
Benign Mucinous 
Cystadenoma
130 Lakshmi 55 8001 P R P2L0 NAD 8x6 Cystic + - - Cx,Vg H NS + 8x7x6.6 193.3 S So - Cystic - 3 5 8 B
TAH BSO 
ICO
Papillary Serous 
Cystadenocarcinoma
131 Mariammal 52 6309 MA IR P3L3 NAD 6x8 Cystic + - - Cx,Vg H Bulky + 6x6x5 94.14 S So - Cystic - 2 5 7 U
TAH BSO 
ICO
Papillary serous tumor 
of borderline 
malignancy
132 Selvam 45 12834 P R P2L1 NAD 8x8 Cystic + - - Cx,Vg H NS + 8x7x6 175.7 S So - Cystic - 3 5 8 B
TAH BSO 
ICO
Papillary Serous 
Cystadenocarcinoma
133 Vellathai 48 4744 P,D R P4L2A2 Cachetic 20x15 Variable - + + Cx,Vg H NS + 20x12x8.5 1066.92 T DE + Complex + 5 5 10 B
TAH BSO 
ICO
Adenocarcinoma
134 Karupayee 60 65607 P PM P4L4 NAD 12x12 Hard - - + Cx,Vg H Atropic + 12x14x8.5 746.84 T ME - Cystic + 5 5 10 B
TAH BSO 
ICO
Mucinous 
Cystadenocarcinoma
135 Ramalan 68 8234 P PM P4L4 NAD 10x15 Firm - - - Cx,Vg H Atropic + 13x8x10.5 571.11 T So + Cystic - 5 3 8 B
TAH BSO 
ICO
Brenner tumor
136 Sathya 13 8078 D R Nulli NAD 20x15 Hard - - + Cx,Vg H NS + 18x15x12.5 1765.13 T ME + Complex + 5 5 10 U RSO ICO
Mucinous 
Cystadenocarcinoma 
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